The present invention relates generally to systems and methods for treating internal tissue defects, such as septal defects.
By nature of their location, the treatment of internal tissue defects is inherently difficult. Access to a defect through invasive surgery introduces a high level of risk that can result in serious complications for the subject. Access to the defect remotely with a catheter or equivalent device is less risky, but treatment of the defect itself is made more difficult given the limited physical abilities of the catheter. The difficulty in accessing and treating tissue defects is compounded when the defect is found in or near a vital organ. For instance, a patent foramen ovale (“PFO”) is a serious septal defect that can occur between the left and right atria of the heart and a patent ductus arteriosus (“PDA”) is an abnormal shunt between the aorta and pulmonary artery.
During development of a fetus in utero, oxygen is transferred from maternal blood to fetal blood through complex interactions between the developing fetal vasculature and the mother's placenta. During this process, blood is not oxygenated within the fetal lungs. In fact, most of the fetus' circulation is shunted away from the lungs through specialized vessels and foramens that are open during fetal life, but typically will close shortly after birth. Occasionally, however, these foramen fail to close and create hemodynamic problems, which, in extreme cases, can prove fatal. During fetal life, an opening called the foramen ovale allows blood to bypass the lungs and pass directly from the right atrium to the left atrium. Thus, blood that is oxygenated via gas exchange with the placenta may travel through the vena cava into the right atrium, through the foramen ovale into the left atrium, and from there into the left ventricle for delivery to the fetal systemic circulation. After birth, with pulmonary circulation established, the increased left atrial blood flow and pressure causes the functional closure of the foramen ovale and, as the heart continues to develop, this closure allows the foramen ovale to grow completely sealed.
In some cases, however, the foramen ovale fails to close entirely. This condition, known as a PFO, can allow blood to continue to shunt between the left and right atria of the heart throughout the adult life of the individual. A PFO can pose serious health risks for the individual, including strokes and migraines. The presence of PFO's have been implicated as a possible contributing factor in the pathogenesis of migraines. Two current hypothesis that link PFO's with migraine include the transit of vasoactive substances or thrombus/emboli from the venous circulation directly into the left atrium without passing through the lungs where they would normally be deactivated or filtered respectively. Other diseases that have been associated with PFO's (and which could benefit from PFO closure) include but are not limited to depression and affective disorders, personality and anxiety disorders, pain, stroke, TIA, dementia, epilepsy, and sleep disorders.
Still other septal defects can occur between the various chambers of the heart, such as atrial-septal defects (ASD's), ventricular-septal defects (VSD's), and the like. To treat these defects as well as PFO's, open heart surgery can be performed to ligate or patch the defect closed. Alternatively, catheter-based procedures have been developed that require introducing umbrella or disc-like devices into the heart. These devices include opposing expandable structures connected by a hub or waist. Generally, in an attempt to close the defect, the device is inserted through the natural opening of the defect and the expandable structures are deployed on either side of the septum to secure the tissue surrounding the defect between the umbrella or disc-like structure.
These devices suffer from numerous shortcomings. For instance, these devices typically involve frame structures that often support membranes, either of which may fail during the life of the subject, thereby introducing the risk that the defect may reopen or that portions of the device could be released within the subject's heart. These devices can fail to form a perfect seal of the septal defect, allowing blood to continue to shunt through the defect. Also, the size and expansive nature of these devices makes safe withdrawal from the subject difficult in instances where withdrawal becomes necessary. The presence of these devices within the heart typically requires the subject to use anti-coagulant drugs for prolonged periods of time, thereby introducing additional health risks to the subject. Furthermore, these devices can come into contact with other portions of the heart tissue and cause undesirable side effects such as an arrhythmia, local tissue damage, and perforation.
Accordingly, improved devices, systems and methods for treating and closing internal tissue defects within the heart are needed.
Improved devices and systems for treating internal tissue defects, such as septal defects and the like, are provided herein by the way of exemplary embodiments. These embodiments are examples only and are not intended to limit the inventive subject matter described herein. Generally, these embodiments include devices for controlling a medical system remotely, devices for improved centering of a delivery device with respect to a septal wall, and improved operation while within a patient.
Other systems, methods, features and advantages of the subject matter described herein will be or will become apparent to one with skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description, be within the scope of the inventive subject matter described herein, and be protected by the accompanying claims.
The details of the subject matter described herein, both as to its structure and operation, may be gleaned in part by study of the accompanying figures, in which like reference numerals refer to like parts. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the subject matter described herein. Moreover, all illustrations are intended to convey concepts, where relative sizes, shapes and other detailed attributes may be illustrated schematically rather than literally or precisely.
Described herein are improved devices and methods for treating septal defects. For ease of discussion, the devices and methods will be described with reference to treatment of a PFO. However, it should be understood that the devices and methods can be used in treatment of any type of septal defect including ASD's, VSD's and the like, as well as PDA's or other structural cardiac or vascular defects.
Treatment system 100 can also optionally include a stabilization device 105 for stabilization of body member 101 during delivery of implant 103 and a centering device 106 for facilitating the centering or the otherwise desired positioning of implant 103 for delivery. Although shown here as four separate components, any combination of body member 101, delivery device 104, stabilization device 105 and centering device 106 can be integrated together to reduce the number of components to three, two or one total components in treatment system 100.
The use of a similar treatment systems 100, capable of having body members 101, implants 103, delivery devices 104, stabilization devices 105 and positioning devices 106, are described in detail in co-pending U.S. patent application Ser. No. 11/218,794, filed Sep. 1, 2005 and entitled “Suture-based Systems and Methods for Treating Septal Defects,” U.S. patent application Ser. No. 11/295,338, filed Dec. 5, 2005 and entitled “Clip-based Systems and Methods for Treating Septal Defects,” and U.S. provisional patent application Ser. No. 60/986,229, filed Nov. 7, 2007 and entitled “Systems, Devices And Methods For Achieving Transverse Orientation In The Treatment Of Septal Defects,” each of which are fully incorporated by reference herein. It should be noted that any of the types of implantable closure devices, systems for delivering the closure devices and methods for using the same that are described in these incorporated applications can be used with the systems and methods described herein.
To better understand the many alternative embodiments of treatment system 100, the anatomical structure of an example human heart having a PFO will be described in brief.
Many different variations of PFO's can occur. For instance, thickness 220 of septum primum 214, thickness 221 of septum secundum 210, overlap distance 222 and the flexibility and distensibility of both septum primum 214 and septum secundum 210 can all vary. In
As will be described in more detail below, treatment of a PFO preferably includes inserting treatment system 100 into the vasculature of a patient and advancing body member 101 through the vasculature to inferior vena cava 202, from which access to right atrium 205 can be obtained. Once properly positioned within right atrium 205, delivery device 104 can be used to deliver implant 103 to PFO region 209, preferably by inserting implant 103 through septum secundum 210 and primum 214 such that implant 103 lies transverse to tunnel 215 and can at least partially close tunnel 215.
Central portion 303 is preferably configured to fit within a manmade or surgically created opening in either septum primum 214, septum secundum 210 or both. Central portion 303 is also preferably configured to apply a force adequate to bring end portions 301-302 towards one another when implanted, to be implantable into septal walls 207 of varying thickness and to fit within elongate body member 101, the diameter of which is preferably minimized for ease of insertion within the patient's vasculature.
Implant 103 can be configured in any manner desired to fit the needs of the application. Implant 103 can have any size and shape and can include additional portions not shown in
Referring back to
The end tips 307 of body 304 are preferably atraumatic so as to minimize injury to cardiac tissue. In this embodiment, end tips 307 are rounded and have a larger diameter than body 304. End tips 307 can also be configured as floppy tips that are curled or coiled and can be flexible or non-flexible. Also, it should be noted that any part of implant 103 can be modified for imaging purposes. For instance, in this embodiment end tips 307 are radio-opaque to increase visibility of implant 103 during imaging. Also, end tips 307 can be configured to facilitate delivery. For instance, in one embodiment end tips 307 can be shaped to minimize the risk of becoming caught on any portion of the delivery device 104. In another embodiment, end tips 307 are configured to interface with the delivery device 104 to allow manipulation of implant 103 before, during or after delivery.
LA portion 302 and RA portion 301 can each be sized in any manner desired. Preferably, LA portion 302 is configured to have relatively larger coiled segment widths 310, include relatively more coiled segments 306 and exert a closure force over a relatively larger area 314 than RA portion 301. This can be for one of at least two reasons. As will be described in more detail below, preferably, LA portion 302 is deployed in PFO region 209 first and, once in contact with septal wall 207, LA portion 302 is used to help deploy, or pull, portions 303 and 301 from delivery device 104. Also, septum primum 214 is typically thinner than septum secundum 210 and more likely to tear or deform to the extent that LA portion 302 can be pulled though septum primum 214.
Preferably, implant 103 is configured to adjust to septal walls 207 having varying degrees of thickness. Accordingly, central portion 303 preferably has a compressibility sufficient to apply a closure force 312 to thinner septal walls 207 while at the same time having an expandability sufficient to accommodate thicker septal walls 207 without excessive permanent deformation. In one exemplary embodiment, which is for purposes of illustration only and should not be used to limit the scope of the inventive subject matter in any way, central portion 303 is expandable from 3 to 8 millimeters (mm) without excessive permanent deformation.
As mentioned above, implant 103 can be deformable between a configuration suited for housing within delivery device 104 and the implanted configuration depicted in
To facilitate the deformation of implant 103 between the housed configuration and the implanted configuration depicted in
In
Central portion 303 is not required to include a coiled section 324 and can, in fact, be only a generally straight section 305. Furthermore, central portion 304 is not required to be formed from a wire-like body 304 and can be configured in any manner desired as depicted in the block diagram of
Referring in more detail to RA portion 301 and LA portion 302,
In
In both
In
RA/LA portions 301/302 are not required to be implemented in a stacked configuration. For instance, in
In the embodiments discussed above, the radius of curvature of the coiled segments 306, present in either RA/LA portions 301/302 or central portion 303, is generally constant or varies at a constant rate, resulting in a circular, spiral or helical appearance when viewed from the side (e.g., direction 330 of
RA/LA portions 301/302 are not required to include coiled segments 306 and are not required to be formed from a wire-like body 304. As mentioned above, RA/LA portions 301/302 can be configured in any manner desired as depicted in the block diagram of
In addition to other parameters, the thickness of implant body 304 can vary as desired. For instance,
Like the thickness, the surface of body 304 can also be varied as desired. The surface can be modified directly or through etching, grinding, additional coatings or add-ons, which are applied to the underlying body 304. The surface can be modified for any purpose including, but not limited to increasing surface friction with tissue, increasing the ability to engage tissue, allowing tissue in-growth, promoting healing, promoting scarring, promoting thrombogenicity, preventing blood passage or shunting around or through implant 103, minimizing thrombus formation, promoting anti-coagulation (e.g., with drugs such as heparin and the like), modifying imaging characteristics (e.g., radio-opacity and the like) and decreasing body surface friction (e.g., with a hydrophilic coating and the like).
As stated above, implant 103 can be configured in any manner desired in accordance with the needs of the application. The following is a non-exhaustive list of just some exemplary factors one of skill in the art may consider in designing, configuring, manufacturing and/or otherwise implementing implant 103.
LA portion 302 can be configured to use compressive force 312 from center portion 303 to hold septum primum 214 against septum secundum 210 and at least partially close or seal PFO tunnel 215. LA portion 302 can also be configured to maintain a stable position as central portion 303 and RA portion 301 are deployed without being pulled through septum primum 210. LA portion 302 can be configured to lie flush against septum primum 214 when deployed and not to distort the native geometry of tunnel 215 to create residual shunts. LA portion 302 can be sized to provide adequate coverage over PFO tunnel 215. (In one exemplary embodiment, which is included as an example only and should not be used to limit the inventive subject matter, LA portion 302 has a maximum width 310 of 1.2 centimeters to accommodate most large PFO tunnels 215.) LA portion 302, in combination with central portion 303 and RA portion 301, can be configured to exert enough closure force 314 to seal PFO tunnel 215 and prevent shunting during normal and valsalva atrial blood pressures. LA portion 302 can also be configured: to be deployable with minimal and consistent push force (e.g., push force on pusher member 406, which will be described in more detail below); so that the shape before and after deployment is predictable; to be devoid of characteristics that cause chronic or excessive tissue irritation, inflammation, etc.; and/or for visibility during imaging procedures.
Central portion 303 can be configured to maintain LA portion 302 and RA portion 301 in a state of contact with septal wall 207 with enough closure force 312 to at least partially close and seal PFO tunnel 215. Central portion 303 can also be configured: with an adequate spring constant (k) to prevent tunnel 215 from opening during normal and valsalva atrial blood pressures; not to distort the native geometry of tunnel 215 and create residual shunts; to be deployable with minimal and consistent push force (e.g., push force on pusher member 406, which will be described in more detail below); for visibility during imaging procedures; to expand or stretch to accommodate variable septal wall thicknesses without excessive permanent deformation; with adequate strength to withstand any motion it may experience in vivo; to allow LA portion 302 or RA portion 301 to tilt, for instance, if the area of delivery is wedge shaped; so that central portion 303 does not pinch or sever any tissue that could embolize, for instance, with a spring constant low enough to prevent severing tissue; to exert adequate closure force 312 to close any residual shunts that exist; and/or with maximized width 310 and minimized strains to optimize fatigue performance.
RA portion 301 can be configured to hold septum secundum 210 against septum primum 214 and at least partially close or seal PFO tunnel 215. RA portion 301 can also be configured: to lie flush against septum secundum 210 when deployed and not to distort the native geometry of tunnel 215 to create residual shunts; to be deployable with minimal and consistent push force (e.g., push force on pusher member 406, which will be described in more detail below); so that the shape before and after deployment is predictable; to be devoid of characteristics that cause chronic or excessive tissue irritation, inflammation, etc.; for visibility during imaging procedures; and/or to resist being pulled through septal wall 207.
Also provided herein are methods of manufacturing implant 103.
With a ribbon-like implant 103, pre-processing can include etching of the NITINOL section. Methods of etching NITINOL materials are readily understood to one skilled in the art. For instance, a sheet of NITINOL is first etched or grinded or otherwise altered to vary the cross-sectional shape, thickness, surface texture and the like of one or more sections present on the sheet. Etching of the NITINOL sheet can allow for the implementation of numerous different cross-sectional shapes, thicknesses, surface textures and combinations thereof. Afterwards, each section of NITINOL can be cut from the sheet and trimmed as desired.
At 352, the NITINOL section is fixed to body shaping device 380 in preparation for heat treatment. Heat treatment of NITINOL can instill the desired at rest configuration to body 304 and is well known to those of skill in the art. Accordingly, body shaping device 380 is preferably shaped such that when the NITINOL section is coiled around body shaping device 380, it is in the final desired at rest configuration. One exemplary embodiment of body shaping device 380 is depicted in
Once wrapped around and fixed to body shaping device 380, at 353, the NITINOL section is then preferably heat treated to instill the desired shape. Heat treating can occur at any time and temperature sufficient to instill the desired at rest shape and level of elasticity in implant 103. In one embodiment, which is included as an example only and should in no way be used to limit the inventive subject matter, heat treating can occur at a temperature range of 500-550 degrees Celsius for approximately five minutes.
At 354, the NITINOL section is preferably cooled, e.g., by rapid quenching in room temperature water, then at 355, the NITINOL section is preferably removed from body shaping device 380 and end tips 307 are trimmed, if necessary, to the desired length to form body 304. Finally, at 356, any post-processing is performed, such as the addition of radio-opaque markers, the shaping of end tips 307 and the addition of any desired coatings or blocking material 326.
Turning now to the devices and methods for delivering implant 103,
In
As shown in
The needle insertion location 419 can be placed in any desired location, but should be chosen based in part on the configuration and size of implant 103 and the degree of overlap between septum primum 214 and septum secundum 210. For instance, in one exemplary embodiment, which is included for illustration only and in no way should be used to limit the inventive subject matter, needle insertion location 419 is placed between 3 and 7 mm from limbus 211. The position of needle insertion location 419 can be determined by the length of arm member 409, which in turn can position distal end 410 using limbus 211 as a point of reference. To allow for added flexibility, the length of arm member 409 can be configured to be adjustable during the implantation procedure. Thus, arm member 409 is preferably configured for at least two functions: (1) to stop travel of body member 101 at limbus 211 by abutting limbus 211 and (2) to position distal end 410 in the desired needle insertion location 419.
As mentioned above, OA delivery member 401 is preferably configured to allow slidable movement of needle member 405, pusher member 406 and implant 103 within inner lumen 402. Preferably, OA delivery member 401 is configured so as to maintain a sufficient degree of structural integrity and kink resistance, while at the same time providing adequate torque or twist control. In one exemplary embodiment, OA delivery member 401 is composed of a flexible braided metal reinforced polymeric tube configured to provide the desired amount of kink resistance and torque control. In other exemplary embodiments, OA delivery member 401 can be composed of a braided or unbraided polymeric tube. In yet another exemplary embodiment, OA delivery member 401 is composed of a metal tube having apertures located therein to provide added flexibility. For instance, OA delivery member 401 can be a NITINOL slotted tube, with the size and spacing of each slot configured for optimal flexibility, kink resistance and torque control. The apertures are preferably placed in a location corresponding to the portion of OA delivery member 401 that extends or arcs out, while the portion of OA delivery member 401 proximal to this can be left solid without apertures to maintain resilience in OA delivery member 401 and provide resistance to push back from needle member 405 as it penetrates septal wall 207.
Furthermore, OA delivery member 401 can be coated to provide low friction surfaces to facilitate advancement of OA delivery member 401 within body member 101 and the patient's body, as well as to facilitate movement of needle member 405 within lumen 402. Pusher member 406 and needle member 405 can be coated as well. For instance,
Like OA delivery member 401, needle member 405 and pusher member 406 are also preferably flexible elongate members.
For instance, needle member 405 can include one or more openings, or apertures 436, to increase flexibility. Here, needle member 405 includes multiple apertures 436 in various arrangements. Needle member 405 can be fabricated from any desired material including, but not limited to, NITINOL and stainless steel, and apertures 436 can be formed in any manner including, but not limited to, molding, milling, grinding, laser cutting, EDM, chemical etching, punching and drilling. The design and use of flexible needles is also discussed in parent U.S. patent application Ser. No. 10/847,747, filed on May 7, 2004.
A first region 437 of needle member 405 includes apertures 436 located at various intervals around the circumference of needle member 405. A second region 438, located distal to the first region 437, includes apertures 436 on the lower portion of needle member 405.
Treatment system 100 can be configured to apply a suction-type force to any surface of septal wall 207 to allow needle member 405 to more easily penetrate the septal tissue without excessive “tenting” of septal wall 207 in response to the pressure applied by needle member 405. For instance, the proximal end of OA delivery member 401 can be coupled with a vacuum or pressure adjustment device configured to lower the air or fluid pressure within OA delivery member 401. The pressure is preferably lowered to a degree sufficient to create a suction-type force between OA delivery member 401 and septal wall 207 thereby keeping septal wall 207 in contact or in proximity with OA delivery member 401 while needle member 405 is advanced into septal wall 207. Also, the suction-type force can be applied through needle member 405 instead of, or in addition to OA delivery member 401.
Treatment system 100 preferably includes one or more sensors to facilitate determination of when needle member 405 has entered left atrium 212. For instance, in one exemplary embodiment, needle member 405 includes a sensor at or near distal end 415. The sensor can be any type of applicable sensor, such as a pressure sensor, thermal sensor, imaging device, acoustic device and the like. In one exemplary embodiment, a pressure sensor is included that is configured to sense the blood pressure change between right atrium 205 and left atrium 212. The pressure sensor can be any type of pressure sensor including, but not limited to, an electrical sensor and a fluid feedback sensor such as a lumen within needle member 405 having an open distal end in fluid communication with the exterior environment. In an alternative exemplary embodiment, distal end 415 of needle member 405 is configured to be visible by an external or internal imaging device, which can then be used to track the position of distal end 415 with respect to septal wall 207.
For instance,
Pusher member 406 can also be configured to releasably couple with implant 103. For instance, in one exemplary embodiment, pusher member 406 is tethered to implant 103 with a tether 485 in order to allow implant 103 to be drawn back into needle member 405 if needed, such as in a case of improper deployment. If implant 103 is properly deployed, tether 485 can be released from pusher member 406. In another exemplary embodiment, pusher member 406 can be configured to both push and pull implant 103 while within needle member 405, as depicted in
Delivery device 104 can be configured to maintain the proper orientation of OA delivery member 401, needle member 405, pusher member 406 and implant 103 during delivery.
The distances that OA delivery member 401, needle member 405 and pusher member 406 are moved proximally and distally with respect to body member 101, can be relatively small. Manual movement of these components, while possible, can be difficult. Treatment system 100 can include one or more automated systems or devices at the proximal end of body member 101 to facilitate movement of these components and lessen the risk that each component is inadvertently advanced too far or not enough. The automated systems or devices can also be configured to apply the desired amount of force to move each component and sense if too much force is being used, which could be indicative of an error in the delivery process.
To further facilitate movement of OA delivery member 401, needle member 405 and pusher member 406, each can be optionally pre-shaped. For instance, in one exemplary embodiment, one or more of OA delivery member 401, needle member 405 and pusher member 406 can include a curved section that corresponds to the desired deflected arc shape of OA delivery member 401 depicted in
It should also be noted that needle member 405 can be excluded from system 100 altogether. Pusher member 406 can deploy implant 103 through a pre-existing hole, or implant 103 can be configured with a substantially sharp end tip 307 for creation of a hole while being deployed by pusher member 406.
As described with respect to
The nature of the tissue forming septum primum 214 can be irregular, for instance including overlapping folds, variations in tissue thickness and variations in distensibility, each of which can cause septum primum 214 to move, or tent, when needle member 405 is advanced through. The inclusion of grasping device 502 can also provide the additional advantage of holding septum primum 214 in place and reducing the risk of tenting.
Grasping device 502 preferably includes a flexible grasping element 506 coupled with inner pull member 505. Here, grasping element 506 is configured as a rectangular element. Outer tubular sheath 501 preferably includes lumen 507 having open distal end 508, from which grasping element 506 can be deployed. Lumen 507 can be configured with contoured sidewalls to facilitate deployment of grasping element 506. To deploy grasping element 506, inner member 505 can be pulled in a proximal direction with respect to outer sheath 501, causing grasping element 506 to advance through lumen 507 and out of distal end 508. Grasping element 506 can optionally include an atraumatic end 512, which in this embodiment is a radio-opaque element, which may be gold or platinum. In this embodiment, grasping element 506 is configured as a deformable, pre-shaped element having three main configurations.
Once the delivery procedure is complete, inner member 505 can be advanced distally with respect to outer sheath 501 to draw grasping element 506 back within lumen 507. Any component of treatment system 100 adequately coupled with stabilization device 105 is thereby also anchored to septum primum 214. One of skill in the art will readily recognize that this and similar embodiments of stabilization device 105 can be used to engage any tissue flap or edge desired, not solely septum primum 214.
Grasping device 502 can be configured in any manner desired in accordance with the needs of the application.
It should be noted that, in order to provide additional surface friction, additional abutments can be included on grasping element 506 and/or the surface of grasping element 506 can be etched or coated or otherwise textured.
As discussed with respect to
When centering device 106 is placed within PFO tunnel 215, centering arms 602 can be extended until coming into contact with sidewalls 219, as depicted in
In this manner, centering device 106 can be centered within PFO tunnel 215 and can be used as a reference point for delivering implant 103. Preferably, centering device 106 is coupled with delivery device 104, so that centering of centering device 106 will also cause centering of delivery device 104. Preferably, once implant 103 is delivered, centering arms 602 are retracted proximally into lumens 603 and centering device can then be retracted through PFO tunnel 215. Surface 610 of recessed portion 605 is preferably curved, or tapered, to reduce the risk that support member 601 will catch or become hung up on any tissue in or around PFO tunnel 215.
Here, the extended portions of centering arms 602 are shown as being located entirely within PFO tunnel 215. One of skill in the art will readily recognize that variation of length 609 of recessed portion 605 will cause the extended portion of centering arms 602 to vary accordingly.
Support member 601 and centering arm 602 can each be composed of any desired material in accordance with the needs of the application. Preferably, support member 601 is composed of a flexible polymer, such as polyimides, polyamides, polypropylene and the like. Preferably, centering arms 602 are composed of a flexible polymer or metal, such as NITINOL, stainless steel and the like.
In the embodiment described with respect to
Also, arms 602 can be pre-shaped to be biased to assume a desired shape when allowed to expand from recessed portion 605. For instance, in one exemplary embodiment, arms 602 are composed of NITINOL and are heat-treated for pre-shaping. One of skill in the art will readily recognize, in light of this disclosure, that variation of the thickness of arms 602 and pre-shaping can allow an almost limitless number of shapes to be achieved, having curved portions, straight portions and any combination thereof which can be symmetric or asymmetric.
As mentioned above, in some cases, sidewalls 219 of PFO tunnel 215 are not equidistant along the length of PFO tunnel 215, causing PFO tunnel 215 to diverge or converge from PFO entrance 217 to PFO exit 218. Divergence or convergence of PFO tunnel 215 can cause centering device 106 to slip out from PFO tunnel 215 when arms 602 are extended.
It should be noted that centering device 106 can include any number of one or more arms 602 for centering/positioning purposes.
In another exemplary embodiment, centering device 106 includes multiple arms 602 configured for use independently of each other to allow the user to have increased control over the position of centering device 106 within PFO tunnel 215. For instance, the user can adjust two opposing arms 602 to center device 106 between sidewalls 219 within tunnel 215, and then adjust a third arm 602 to position device 106 as desired relative to septum secundum 210 and septum primum 214. In another case, the user can use three or more arms 602 for centering based on the tunnel type or anatomy.
In some embodiments, it can be desirable to keep centering device 106 within PFO tunnel 215 while needle member 405 is advanced through septal wall 207. To reduce the risk that needle member 405 will contact centering device 106 during this procedure, support member 601 can be configured to deflect needle member 405.
It should be noted that the functionality of the various embodiments described herein can be combined and integrated together to reduce the number of components in treatment system 100, simplify the design of treatment system 100 and so forth. For instance,
For stabilization and centering, support member 601 is preferably advanced through PFO exit 218. Once in left atrium 212, centering arms 602 can be advanced distally to deploy grasping elements 506 from the first, housed configuration, to the second and third configurations for catching and grasping septum primum 214. Once septum primum 214 is grasped, support member 601 can be retracted proximally with respect to centering arms 602 in order to deploy centering portions 618 of each arm 602. The centering portions 618 can then expand outwards and center device 106, thereby preferably also centering body member 101 and delivery device 104, while at the same time maintaining a grasp of septum primum 214.
As discussed with respect to
It should be noted that in each of the embodiments described with respect to
In addition, treatment system 100 can include multiple delivery devices 104 for delivery of multiple implants 103, multiple stabilization devices 105 for stabilization on multiple tissue surfaces, multiple centering devices 106 and multiple body members 101 as desired. If treatment system 100 is used to access septal wall 207 via inferior vena cava 202, the maximum radial cross-section size of body member 101 is preferably 13 French or less, although it should be noted that any size body member 101 can be used in accordance with the needs of the application. Body member 101 can be constructed from any material as desired, but is preferably constructed from a flexible polymer such as polyethylene, polypropylene, nylon and the like.
Furthermore, it should be noted that any component or component portion within treatment system 100 can be configured to facilitate any type of imaging, including, but not limited to, internal and external ultrasound imaging, optical imaging, magnetic resonance imaging (MRI), and fluoroscopy. For instance, radio-opaque portions can be used to increase the visibility in fluoroscopic applications while echolucent coatings can be used to increase visibility in ultrasound applications. As an example, in one exemplary embodiment OA delivery member 401 can be entirely radio-opaque, or can include portions that are radio-opaque, such as on distal tip 430 of
Also described herein are methods 700 and 800 of treating PFO tunnel 215, preferably by at least partially closing PFO tunnel 215. Methods 700 and 800 are preferably used with treatment system 100, but can be used with any medical system as desired. For ease of discussion, method 700 will be described with respect to treatment system 100 and method 800 will be described without reference to a particular treatment system, although it should be understood that methods 700 and 800 can be used with or without treatment system 100. Generally, the steps of methods 700 will vary, in part, on the actual configuration of implant 103, the number of implants 103 to be delivered, the location in which each implant 103 is to be delivered, the use of guidewire 641 or a guide catheter and the optional use of stabilization device 105 and/or centering device 106 or any combination thereof.
In
Also, as many implants 103 can be used in any arrangement as desired.
Although there are many different implementations and variations of method 700, for ease of discussion, method 700 will be described herein as using one implant 103, delivered through both septum primum 214 and septum secundum 210, using an exemplary embodiment of treatment system 100 similar to that described above with respect to
At 702, guidewire 641, if present, can be removed. At 704, stabilization device 105 is preferably advanced through lumen 631 and into left atrium 212. At 706, body member 101 can be retracted proximally into right atrium 205. Preferably, stabilization device 105 includes a stabilization member 501 and grasping device 502 with grasping element 506. At 708, grasping element 506 can be deployed from the first housed configuration to the second configuration for catching tissue, which, in this example, is preferably septum primum 214.
Next, at 710, stabilization member 501 is preferably moved distally until grasping element 506 catches septum primum 214. Then, at 712, OA delivery member 401 can be retracted proximally with respect to body member 101 to raise arm member 409. At 714, body member 101 and OA delivery member 401 are advanced distally until arm member 409 abuts limbus 211. At 716, centering device 106 can be used to center delivery device 104, preferably by deflecting centering arms 602. Once centered, if not already done so, at 717 stabilization device 105 can be fixably coupled to delivery device 104 (e.g., with a rotating hemostasis valve or Tuohy-Borst valve and the like). Next, at 718, grasping element 506 can be further deployed to the third configuration to grasp septum primum 214 and lock stabilization device 105 to septum primum 214. Alternatively, either 716, 717, 718 or any combination thereof can be implemented prior to 712. Also, 716-718 can be implemented in any order desired with respect to each other.
Once stabilized, centered and locked in place, OA delivery member 401 is preferably advanced distally with respect to body member 101 to rotate distal end 410 into the desired orientation with surface 320 of septum secundum 210. At 722, needle member 405 can be advanced through septum secundum 210 and septum primum 214 and into left atrium 212. Then, at 724, pusher member 406 can be advanced distally to at least partially deploy LA portion 302 of implant 103 from distal end 415 of needle member 405. In embodiments where centering arms 602 are in their deflected state for centering, it is possible for needle member 405 to pass between centering arms 602 and stabilization member 501 when inserted, based on needle insertion location 419. To avoid capture of implant 103 between centering arms 602 and stabilization member 501, centering arms 602 can be retracted proximally back into elongate body 101 thereby removing them from seats 604 and preventing implant 103 from being trapped between centering arms 602 and stabilization member 501. Next, at 726, grasping element 506 can be moved to the second configuration to free stabilization device 105 from septum primum 214. Alternatively, 726 can be performed before 724 if desired.
Then, at 728, LA portion 302 can be fully deployed if not already. At 730, grasping element 506 can be removed to the first configuration, housed within stabilization member 501. Next, at 732, centering device 106 can be moved to the undeployed configuration if not already, preferably by collapsing centering arms 602, after which stabilization device 105 can be retracted proximally from PFO entrance 217 at 734. At 736, needle member 405 can be withdrawn into OA delivery member 401 to deploy central portion 303 of implant 103 and at least a portion of RA portion 301. Here, at 738, an optional closure test can be performed to confirm at least partial closure, and preferably substantially complete closure, of PFO tunnel 215. Any desired closure test can be performed including, but not limited to, the introduction of gaseous bubbles simultaneously with imaging using contrast enhanced trans-cranial doppler (CE-TCD), intracardiac echocardiography (ICE) and the like, or the infusion of a radio-opaque dye imagable via fluoroscopy. The test may be performed by pulling back OA delivery member 401 as far as necessary to deploy RA coil 301 and then test while device is at PFO entrance.
At 740, OA delivery member 401 can be retracted proximally with respect to body member 101 to complete deployment of RA portion 301, release limbus 211 and place OA delivery member 401 in the original position. If the desired degree of closure is confirmed, then any tether connection to implant 103 can be released at 742. Finally, at 744, body member 101 can be retracted distally and withdrawn from the patient.
Control of system 100 can be accomplished with the use of a proximal control device, or proximal controller, 900.
Although not limited to such, proximal controller 900 will be described in the context of use with an embodiment of body member 101 and delivery device 104 similar to that described with respect to
In the embodiment depicted in
Proximal controller 900 includes two guide rails 907 and a user interface 909 including three slidable actuators 940, 960, and 980 configured to slide along guide rails 907. Guide rails 907 are preferably rigid members with a smooth surface to allow for low surface frictional resistance to the movement of actuators 940, 960, and 980. When portions 902 and 903 are coupled together, guide rails 907 are preferably held in place by restraining seats 908 located in both portions 902 and 903 (seats 908 are obscured and not shown in upper portion 902). Also, actuators 940, 960, and 980 are maintained sequentially within housing 901 and can be controllably moved, or slid, along guide rails 907.
In this embodiment, control of each actuator 940, 960, 980 is accomplished by way of depressible buttons 941, 961 and 981, respectively. Access to actuators 940, 960 and 980 is achieved through opening 926 in upper housing portion 902. One of skill in the art will readily recognize that other forms of controlling actuators 940, 960, 980 can be used.
Each of actuators 940, 960, 980 is preferably coupled with a portion of delivery device 104. In this embodiment, actuator 940 is coupled with OA delivery member 401, actuator 960 is coupled with needle member 405 and actuator 980 is coupled with pusher member 406. To facilitate the description herein, actuator 940 will be referred to as OA actuator 940, actuator 960 will be referred to as needle actuator 960 and actuator 980 will be referred to as pusher actuator 980. Of course, any of actuators 940, 960, and 980 can be coupled with any portion of delivery device 104, or any other portion of system 100, as desired.
Preferably, proximal controller 900 is configured such that the movement of actuators 940, 960, and 980 with respect to each other can be controlled, or guided, at appropriate stages during an implantation procedure. At certain stages, movement of the various actuators 940, 960, and 980 is fully independent of the positions of one or more of the remaining actuators 940, 960, and 980. Conversely, at certain stages, movement of the various actuators 940, 960, and 980 is dependent on the positions of one or more of the remaining actuators 940, 960, and 980 and movement can be restricted to certain directions or prevented entirely. Also, controller 900 is preferably configured such that the movement of actuators 940, 960, 980 with respect to the anatomy of the subject can be controlled, or guided, at appropriate stages during the procedure. These features can reduce the risk that the user improperly operates system 100 while within the body of the subject, such as by prematurely releasing implant 103.
In this embodiment, control is also provided by a network of mechanical tabs, slots, abutments, surfaces and/or ribs which can act in conjunction to control and lock the movement of each actuator 940, 960 and 980. Before describing the operation of controller 900, each portion of controller 900 will be described in greater detail.
Upper housing portion 902 includes three slots 910, 911 and 912 (shown here partially obscured) located on both sides of opening 926. Housing portion 902 also includes multiple guide markings 931-937 which can correspond to one of guide markings 942, 962 and 982 located on each of actuators 940, 960 and 980, respectively. In this embodiment, guide markings 931-932 have a circular shape and correspond to circular marking 982 on pusher actuator 980, guide markings 935-936 have a triangular shape and correspond to triangular marking 962 on needle actuator 960, and guide markings 933, 934, and 937 have a rectangular shape and correspond to rectangular marking 942 on OA actuator 940.
Lower housing portion includes two sets of ribs, inner ribs 913 and outer ribs 914. Ribs 913-914 extend upwards from the base of lower housing portion 903. Inner ribs 913 each include two slots 915 and 916. The distal ends 917 of ribs 913 are located distal to the distal ends 918 of ribs 914. The proximal ends 919 of ribs 913 are also located distal to the proximal ends 920 of ribs 914. Located beneath and to the outside of ribs 914 are a set of abutments 925 for abutting OA actuator 940.
An aperture 922 is located at the distal end of lower housing portion 903 and is configured to allow routing of body member 101 therethrough. Lower housing portion 903 also includes a base 921 upon which it can rest and remain stable during the implantation procedure.
OA actuator 940 includes a set of outwardly extending tabs 943 located at the base of button 941. OA actuator 940 also includes two proximally located rails 944 each having two similarly shaped slots 945 and 946 (not shown) located therein. Slot 945 is located proximal to slot 946 and both are located in the bottom portion of rails 944. On both sides of OA actuator 940 are a set of guide rail abutments 947 that facilitate, or guide, the movement of OA actuator 940 along each guide rail 907. Below guide rail abutments 947 on each side is a proximally located tab 948 for abutting abutments 925.
Needle actuator 960 includes a set of outwardly extending tabs 963 located at the base of button 961. Needle actuator 960 also includes two distally located rails 964 and two proximally located rails 965. The distal end of each distal rail 964 includes a downwardly oriented chamfer 966, which can be used to force OA actuator 940 into a locked position in the case where the user has not fully done so. Distal rails 964 are spaced apart at a greater distance than proximal rails 944 (on OA actuator 940) to allow both sets of rails 944 and 964 to slide distally and proximally in a relatively unimpeded manner. OA proximal rails 944 are aligned with tabs 963 on needle actuator 960 and are configured to interact with tabs 963. Needle actuator 960 is configured to slide along rails 944 with tabs 963 in position to interact with slots 945-946. Likewise, OA actuator 940 is also configured to slide along needle actuator rails 964 and to abut chamfer 966 if needed.
Needle actuator proximal rails 965 each include two slots 967 and 968, both of which are located in the bottom portion of rails 965. The proximal surfaces of slots 967 extend further downwards than the other surfaces on rails 965 to provide a locking function that will be described in more detail below. On either side of needle actuator 960 are a set of guide rail abutments 969 that facilitate, or guide, the movement of needle actuator 960 along each guide rail 907.
Pusher actuator 980 includes a set of outwardly extending tabs 983 located at the base of button 981. Tabs 983 are aligned with needle proximal rails 965 and are configured to interact with slots 967-968. Pusher actuator 980 is also configured to slide over proximal rails 965 to allow the interaction of tabs 983 with slots 967-968. On either side of pusher actuator 980 are a set of guide rail abutments 984 that facilitate, or guide, the movement of pusher actuator 980 along each guide rail 907.
Here, needle member 405 is coupled with and surrounded by a sleeve 990, which is preferably formed of a rigid material, such as stainless steel and the like, and preferably smooth to decrease surface friction. A set screw 991 is adjustably located above sleeve 990 in a slot 992 within needle actuator 960. Set screw 991 is preferably adjusted and brought into contact with sleeve 990 to lock sleeve 990 in place within needle actuator 960. One of ordinary skill in the art will readily recognize that any technique can be used to lock sleeve 990 with needle member 405, or otherwise couple needle member 405 with needle actuator 960, including, but not limited to, bonding, welding, clamping, crimping, and the like.
Likewise, OA delivery member 401 and pusher member 406 are also both preferably coupled with their respective actuators 940 and 980, using similar sleeves in combination with set screws. One of skill in the art will readily recognize that numerous different techniques, including adhesives, welding, soldering, mechanical couplings and the like, can be used to lock each actuator 940, 960, and 980 with the respective component of system 100, in this case OA delivery member 401, needle member 405 and pusher member 406.
Turning now to the use of controller 900, an exemplary method of operating controller 900 is described with the aid of
In
Also in this position, tabs 963 on needle actuator 960 are located within slots 945 within OA proximal rails 944. Depression of needle button 961 in this position is prevented by outer ribs 914, which abut tabs 963. This effectively locks actuator 960 in position with respect to OA actuator 940. With regards to pusher actuator 980, tabs 983 are located within slots 967 within needle proximal rails 965. Depression of needle button 981 in this position is prevented by inner ribs 913, which abut tabs 983, effectively locking pusher actuator 980 in position with respect to needle actuator 960, which in turn is locked in position with respect to OA actuator 940. Thus, here, the position of needle actuator 960 and pusher actuator 980 is locked with respect to OA actuator 940 and follows the movement of OA actuator 940.
In
Needle actuator 960 and pusher actuator 980 have been transitioned to positions slightly proximal that of the previous position, and remain locked in place with respect to OA actuator 940. Thus, the relative positions of needle member 405 and pusher member 406 have remained locked in place relative to OA delivery member 401, and both needle member 405 and pusher member 406 have been retracted within the subject's anatomy in lockstep fashion with OA delivery member 401. The device is then advanced distally to abut the limbus.
In
In the position of
Needle actuator 960 and pusher actuator 980 remain locked in position with respect to OA delivery member 401 and have been transitioned to positions distal that of the previous position. Needle button 961 is now depressible because tabs 963 are located distal to distal ends 918 of outer ribs 914. If the user depresses needle button 961, proximal travel of needle actuator 960 is prevented by the proximal surface of slot 945 (which extends further downwards than the distal surface of slot 945) and distal end 918 of outer rib 914, which abut tabs 963. Pusher actuator 980 remains locked in place with respect to OA actuator 940 and needle actuator 960. If a guidewire is being used, it is preferably removed prior to proceeding to the next step.
In
It should be noted that proximal controller 900 can also be configured to automatically advance needle member 405 by the desired amount. For instance, needle member 405 can be spring loaded such that movement of needle actuator 960 to a certain position releases the spring, which provides force sufficient to advance needle member 405 through septal wall 207. Of course, one of skill in the art will readily recognize that other techniques for automatically advancing needle member 405 can be implemented and, accordingly, the systems and methods described herein are not limited to spring-based techniques.
Pusher actuator 980 has been transitioned with needle actuator 960 to a position distal that of the previous position. Specifically, pusher tabs 983 are now located over top of slot 915 in inner ribs 913, enabling the depression of pusher button 981. If the user depresses pusher button 981, proximal travel of pusher actuator 980 is prevented by the proximal surface of slot 967, which extends further downwards than the distal surface of slot 967. Preferably, button 981 is not depressible far enough to force tabs 983 below the bottommost portion of the proximal surface of slots 967, effectively preventing proximal movement of pusher actuator 980.
In
In
Pusher actuator 980 remains locked in place with respect to needle actuator 960 and has been transitioned with needle actuator 960 to a position proximal that of the previous position. Specifically, pusher tabs 983 remain within slots 968 but are now located over inner ribs 913 at a position proximal that of slots 915, preventing the depression of pusher button 981 and effectively locking pusher actuator 980 in place with respect to needle actuator 960.
In
In this embodiment, the proximal surface of slot 916 extends further upwards than any other surface on inner ribs 913 and acts to block further travel of actuators 940, 960, and 980. This creates a stopping point in the operation of the device immediately prior to full deployment of implant 103, which, among other things, can allow the user time to image the subject to ensure implant 103 is positioned as desired. Needle button 961 is not depressible at this point due to the presence of outer ribs 914, effectively locking tabs 963 in place within slots 945 on OA proximal rails 944. Pusher button 981 is depressible as tabs 983 are now located over slots 916 in inner ribs 913, although movement in the distal and proximal directions is prevented by the contact of tabs 983 with slots 916. Pusher guide marking 982 is preferably aligned with marking 931 on upper housing 902.
In
In this position, OA guide marking 942 is aligned with guide marking 933 on upper housing 902 and OA tabs 943 are seated within slots 910 in upper housing 902. OA button 941 remains depressible but the user is prevented from transitioning OA actuator 940 any further proximally than this position by the contact of tabs 948 with abutments 925 on housing portion 903. Needle actuator 960 remains locked in position with respect to OA actuator 940 and moves proximally with OA actuator 940. Needle button 961 is not depressible due to the outer ribs 914 and is effectively locked in place within slots 945 of OA proximal rails 944. Pusher actuator 980 remains locked in the same position as that depicted in
In
Adjacent to knob 1006 is information display 1103, which can be used to provide information to the user regarding any facet of device operation or the procedure. Display 1103 can have any configuration desired, including, but not limited to a mechanical and/or electronic display. In this embodiment, display 1103 is a window or opening in upper housing 902 through which an imprinted guide can be seen by the user, the guide changeable with rotation of knob 1006 and capable of displaying information regarding what step in the closure procedure the user is currently performing. Optionally, the window can be configured as a lens that magnifies the image for the user.
Each actuator 1140, 1160 and 1180 can include an interface 1141, 1161 and 1181, respectively, that interfaces with one of the respective slots 1114, 1116 and 1118 (shown in
The embodiment shown in
At the outset of the closure procedure, interface wheels 1141, 1161 and 1181 are all preferably located in their respective slots 1114-1118 at reference line A1. These positions correspond to a low profile arrangement of members 401, 405 and 406 suitable to be maintained during advancement of body member 101 through the vasculature and into proximity with septal wall 207, preferably within right atrium 205. Once in proximity with septal wall 207, knob 1006 can be rotated to bring wheels 1141, 1161 and 1181 to a position along reference line B1 in the respective slots 1114-1118. These B1 positions are all proximal to the respective A1 positions. OA actuator 1140 has moved proximally and actuated the raising and proximal movement of OA delivery member 401 to raise arm member 409 and place it in position to engage limbus 211, similar to the orientation depicted in
Needle actuator 1160 and pusher actuator 1180 have moved proximally as well, such that all three members 401, 405 and 406 remain in the same positions with respect to each other. It should be noted that the use of actuators 1140, 1160 and 1180 interfacing with predefined slots 1114-1118 in the manner described here eliminates the need to lock each member 401, 405 or 406 with respect to another member, since the relative position of each member 401, 405 and 406 is controlled by the radial position of knob 1006 (and cam 1104).
After body member 101 has been advanced distally such that arm member 409 abuts limbus 211, knob 1006 is preferably rotated to the position of reference line C1. This rotation transitions OA actuator 1140 distally causing OA member 401 to enter an off-axis delivery orientation, similar to the orientation depicted in
One of skill in the art will readily recognize that the slope of slots 1114-1118 can determine the distal/proximal (i.e., longitudinal) rate of movement at which the respective member 401, 405 and 406 will move in relation to the rate of rotation of knob 1006. A relatively more longitudinal (vertical as depicted here) slope corresponds to a relatively greater distance while a relatively more lateral (horizontal as depicted here) slope corresponds to a relatively shorter distance. The rate at which members 401, 405 and 406 are transitioned can be dependent upon the individual application.
Rotation of knob 1006 to reference line D1 causes needle actuator 1160 to transition distally to advance needle member 405 out of OA delivery member 401 and through septal wall 207, preferably through both septum secundum 210 and septum primum 214. As in other embodiments described herein, it should be noted that proximal controller 900 can also be configured to automatically advance needle member 405 by the desired amount. For instance, needle member 405 can be spring loaded such that movement of needle actuator 1160 to a certain position releases the spring, which provides force sufficient to advance needle member 405 through septal wall 207. Of course, one of skill in the art will readily recognize that other techniques for automatically advancing needle member 405 can be implemented and, accordingly, the systems and methods described herein are not limited to spring-based techniques.
At position D1, pusher actuator 1180 has been transitioned with needle actuator 1160 to a position distal that of the previous position, such that the positions of needle 405 and pusher 406 with respect to each other are the same as in position C1, although both have been transitioned distally together while OA member 401 has not moved. As can be seen in
Rotation of knob 1006 to reference line E1 causes pusher actuator 1180 to transition distally causing pusher member 406 to advance LA portion 302 of implant 103 out of needle member 405, which, depending on the specific embodiment of implant 103, allows LA portion 302 to expand within left atrium 212. OA actuator 1140 remain in the same position as position D1, while needle actuator 1160 is transitioned proximally by a relatively small amount to facilitate deployment of LA portion 302.
Rotation of knob 1006 to reference line F1, first causes needle actuator 1160 to retract proximally while pusher actuator 1180 remains stationary, then causes pusher actuator 1180 to retract proximally as well. This sequential motion can first further deploy LA portion 302 and center portion 303, and then retracts implant 103 to cause LA portion 302 to contact septum primum 214. OA actuator 1140 remains stationary between positions E1 and F1.
Rotation of knob 1006 from position F1 to position G1 causes needle actuator 1160 and pusher actuator 1180 to proximally retract, at least partially, into OA member 401. OA actuator 1140 is proximally refracted by a relatively smaller amount than actuators 1160 and 1180. In this embodiment, implant 103 is preferably coupled with pusher member 406 to prevent complete deployment until desired.
Rotation of knob 1006 from position G1 to position H1 and then on to position I1 causes OA actuator 1140, needle actuator 1160 and pusher actuator 1180 to proximally retract to transition OA delivery member proximally from the OA delivery orientation. Here, pusher 406 is retracted proximally by the greatest amount, while needle 405 is retracted proximally by a slightly less amount and OA member 401 is refracted proximally by a slightly less amount than needle 405. Needle 405 is preferably again fully housed within OA member 401. In this embodiment, central portion 303 of implant 103 is preferably flexible and allows implant 103 to bend prior to being released from pusher 406.
Rotation of knob 1006 from position I1 to position J1 causes pusher actuator 1180 to advance distally while OA actuator 1140 and needle actuator 1160 are refracted proximally and then held in a constant position. This can expose the distal end of pusher 406 and allow RA portion 301 of implant 103 to be released, thereby fully deploying implant 103 (with the exception of any safety devices, such as a tether, that still connect implant 103 to delivery device 104).
Rotation of knob 1006 from position J1 to position K1 distally advances OA actuator 1140 and needle actuator 1160 to positions similar to the start position A1, placing OA member 401 in the low profile position suitable for withdrawal through the anatomy of the subject with needle 405 located within OA member 401. Pusher actuator 1180 has been proximally retracted to cause pusher 406 to retract into OA member 401 for withdrawal from the subject.
Turning now to the embodiment shown in
At position E2, pusher actuator 1180 has been advanced to its most distal position and needle actuator 1160 has been retracted from its most distal position by a relatively small amount, to ensure full deployment of the LA portion 302 of the clip 103. OA actuator 1140 remains in a relatively constant position from C2 until H2.
Rotation of knob 1006 from position E2 to position F2 moves pusher actuator 1180 proximally while maintaining needle actuator 1160 in a constant relative position. If a beveled needle member is used, this movement preferably causes the clip 103 to be retracted into the beveled portion of the needle such that the needle can facilitate maintenance of a proper orientation of clip 103, i.e., help resist rotation of clip 103 during deployment against the septal wall.
Such a configuration is depicted in
Rotation of knob 1006 from position F2 to position G2 moves both pusher actuator 1180 and needle actuator 1160 proximally back through the septal tissue the same distance (and at the same rate), preferably to bring LA portion 302 of clip 103 into contact with the septum primum.
Rotation of knob 1006 from position G2 to position H2 moves needle actuator 1160 back proximally while maintaining pusher actuator 1180 in a relatively constant position to bring the needle member 405 into the OA delivery member 401.
Rotation of knob 1006 from position H2 to position 12 moves each of the three actuators 1140, 1160 and 1180 proximally the same distance (and at the same rate), to cause the OA delivery member to exit the OA delivery position and transition to the configuration similar to that depicted in
Rotation of knob 1006 from position 12 to position J2 preferably does not move any of the actuators 1140, 1160 and 1180, but places OA actuator 1140 and pusher actuator 1180 in positions adjacent longitudinal portions of slots 1114 and 1118 that allow actuators 1140 and 1180 to move proximally and distally, respectively. This allows OA delivery member 401 to fully collapse to the elongate, unraised state when withdrawn through the vasculature.
Once in position J2, the user preferably manually retracts delivery device 104 proximally. Because LA portion 302 is deployed against the septum primum 214 and still attached to pusher member 406, the manual retraction of the delivery device 104 causes OA member 401 and needle member 405 to move proximally with respect to pusher member 406. This causes RA portion 303 of clip 103 to become exposed from within OA delivery member 401 (and needle member 405) where it is no longer restrained and free to deploy. (It should be noted that in other embodiments, pusher member 406 can be configured such that clip 103 is released only upon user actuation of a release mechanism.) RA portion 303 can then deploy against the septum secundum to complete delivery.
In this configuration, movement of actuators 1240-1280 is dependent, in part, on the positions of abutments 1214 and 1216 within slots 1204 and 1206 respectively, as well as the position of abutments 1215 and 1217 within track 1203. In addition, bias members 1208 and 1209, depending on the relative bias strengths thereof, will also influence the order of movement of actuators 1240 and 1260, respectively.
Track 1203 and slots 1204 and 1206 are preferably laid out to provide an desired order of movement to each of actuators 1240-1280, either in unison or in relative motion with each other. To operate, a user preferably depresses interface button 1201 and advances user interface 1201, as well as pusher actuator 1280 which is coupled with interface 1201, in a distal direction. As with the other embodiments of controller 900 described herein, the movement of the actuators is dependent on the order of steps in the desired treatment or closure procedure.
In
The rate at which each actuator 1240-80 moves can be varied according to the slope of the respective slots and track. Additional abutments, such as abutments 1224 in lower housing 903 shown in
Thus, as will be readily apparent to one of skill in the art based on the description herein, the layout of slots 1204-1206, track 1203 and the configuration of bias members 1208-1209 can allow numerous desired combinations of movement of actuators 1240-80 to be achieved. A wide variety of different procedures can be performed with the embodiments of proximal controller described herein, including, but not limited to those in the heart.
It should be noted that proximal controller 900 is not limited to the exemplary embodiments described with respect to
Referring back to configuration of the distal portion of system 100,
Any portion of system 100 can be configured to increase the surface friction with septal wall 207. Here, elongate support section 411 of body member 101 includes multiple abutments, or teeth 1012 to aid in engaging the inner wall of tunnel 215, such as the wall of secundum 210. In this embodiment, teeth 1012 are triangularly configured although one of skill in the art will readily recognize that any configuration of teeth 1012 can be used. Also, any surface of system 100 can be configured to increase the surface friction with septal wall 207, such as by the use of abrasive coatings or textures formed without coatings. For instance, a polymeric sheet can be coupled between arm members 409 such that it extends across the gap between arm members 409 and thereby increases the surface friction with septal wall 207 as well as stabilizes the position of each arm member 409 with respect to the other. Any polymeric sheet or strands of polymeric material can be used including (but not limited) to polyester fabrics and the like.
Also in this embodiment, distal cap 430 of OA delivery member 401 is configured to be atraumatic. This reduces the risk of damaging bodily tissue during the implantation procedure or while routing OA delivery member 401 within the subject's vasculature. Here, the portion of distal cap opposite elongate support section 411 has an atraumatic beveled distal surface 1014.
In this embodiment, grasping device 404 includes two arm members 409 having a generally curved shape to accommodate limbus 211. The underside of each arm member 409 includes abutments 420 configured as teeth to aid in engaging septal wall 207. Here, hinge 408 is a swivel-type hinge that allows distal cap 430 of OA delivery member 401 to swivel, or rotate, about arm member 409. Hinge 407 is formed by the intersection of arm member 409 with a base portion 1015. Arm member 409 is configured to flex at this intersection from the at-rest state depicted here. This allows OA delivery member 401 to be raised up and away from body member 101 when proximal force is applied, but also biases OA delivery member 401 to return to the at-rest state, both facilitating engagement with limbus 211 and return of OA delivery member 401 to this low-profile configuration prior to withdrawal from the subject.
If desired, the angle at which OA delivery member 401 is oriented with respect to body member 101 after advancement of OA delivery member 401 into the off-axis position, can be adjusted by varying the lengths of each arm member 409. For instance, if an arm member 409 on the left side were relatively longer than arm member 409 on the right side, when deployed into the off axis configuration OA delivery member 401 would tilt to the left. One of skill in the art will readily recognize that by varying the degree to which the arm members 409 differ in length, one can vary the amount of tilt introduced into OA delivery member 401. This tilt can be used to cause needle 405 to penetrate septal wall 207 at any angle desired or needed for the particular application.
Although not shown, interface 1025 can be further strengthened with the use of a tubular support member surrounding interface 1025. For instance, in one exemplary embodiment, a polymeric tube (e.g., polyester, polyethylene and the like) can be heat shrunk or bonded around the relatively rigid interface 1025 to provide strain relief.
It should be noted that the location of interface region 1025 along the longitudinal axis of needle member 405 can be chosen as desired. In one embodiment, the location of interface region 1025 is close enough to distal tip 415 to have a minimal effect on the flexibility of needle member 405, while at the same time being far enough from distal tip 439 to minimize the risk of any portion of implant 103 or pusher member 406 catching on surface junction 1026 during delivery. The actual location of interface region 1025 is dependent on the size of implant 103, the length of needle member 405 that enters a curved state during delivery, the angle of the sharp beveled surface of needle member 405, as well as other factors.
Referring back to
Elongate support section 1017 can routed through a lumen 1018 (shown to be obscured with dashed lines) in distal end tip 1011. This allows the coupling of elongate support section 1017 with body member 101 to further strengthen the coupling of distal end tip 1011 with the remainder of body member 101. It should be noted that any technique, other than ones using adhesives, can be utilized to couple arm members 409 with body member 101.
The various tubular bodies used in system 100, such as tubular body 1010, 1016, and 1021, are preferably composed of flexible, durable, bio-compatible materials including, but not limited to, NITINOL, stainless steel, and polymers such as PEBAX, polyester, polyvinylchloride (PVC), polyethylene, polyetheretherketone (PEEK), polyimide (PI), nylon (with or without reinforcing materials such as braided or coiled stainless steel, kevlar, carbon fiber and the like). Some materials, such as PEEK, can be manufactured with a curve in a desired direction. Preferably, system 100 is manufactured so that the curve of the outer sheath is aligned in a predetermined manner to be consistent with any curved path the respective outer sheath is designed to follow. For instance, needle tubular body 1020, if manufactured from a material displaying a curve, it is preferably aligned such that the curve is oriented similarly to the curved path needle member 405 follows in the exemplary embodiment described with respect to
Distal end section 1030 includes a lower portion 1032 pivotably coupled with an upper portion 1033. Both portions 1032 and 1033 can include one or more teeth 1012. In the instance where a plurality of teeth 1012 are present, as shown here, teeth 1012 on upper portion 1033 are preferably located in positions complimentary to teeth 1012 located on lower portion 1032 to allow for a greater interface between the two portions 1032-33 and a smaller overall profile. Portions 1032 and 1033 can be constructed from any desired material, including but not limited to NITINOL, stainless steel, polymeric materials or combinations thereof. For instance, in one exemplary embodiment, portions 1032 and 1033 are each constructed from a rigid polymeric material while teeth 1012 are constructed from stainless steel.
Lower portion 1032 and upper potion 1033 can be pivotably coupled together in any manner desired, including use of a living hinge or a hole and rod/strut mechanism (as shown here). Here, the hinge is formed through a single strut 1034 on upper portion 1033, although any number of struts 1034 can be used, as one of skill in the art will recognize the number and placement of struts 1034 can result in increased stability.
In this embodiment, distal tip 430 is also pivotably coupled with upper portion 1033 by way of a hinge (although, again, one of skill in the art will readily recognize the multiple manners in which distal tip 430 can be pivotably coupled with upper portion 1033). Here, distal tip 430 also includes teeth 1012 to provide increased friction with body tissue. Upper portion 1033 includes an open region 1035 in which distal tip 430 preferably partially resides. This allows distal tip 430 to be disposed proximal to distal tip 1031 thereby allowing a greater surface of body tissue to be engaged by distal end section 1030. Also of note is that lower portion 1032 is configured to provide an open region 1036. Open region 1036 is positioned adjacent distal tip 430 and allows needle member 405 (not shown) to pass distal end section 1030.
The placement of distal tip 430 in a position proximal to distal end 1031 allows the height of upper portion 1033 in the capture position to be increased, making it more difficult for distal end section 1030 to inadvertently pass into the PFO tunnel. For instance, the distance from base 1029 of upper portion 1033 to the furthest point on the opposite end of upper portion 1033 that engages tissue can be referred to as the clamp distance 1028 of the device. If clamp distance 1028 is too short, distal end section 1030 may not be able to properly engage secundum 210. For instance, the limbus may be too thick to allow any grasping to occur or, alternatively, distal end section 1030 may be able to grasp the limbus, but not with enough force and surface friction to maintain an effective and reliable “lock” on the septum secundum during the course of the procedure. An adequate clamp distance 1028 preferably allows the user to maintain an effective lock on the secundum 210 to prevent non-negligible slippage during the procedure. This is also dependent on the configuration of the surfaces of upper portion 1033 and lower portion 1032, i.e., whether teeth 1012 or some other friction increasing structure, coating or texture is present, and the degree to which surface friction is thereby increased by said friction increasing means.
Preferably, device 404 is configured to achieve a puncture distance, i.e., the distance from the edge of the limbus to the point on the outer surface of the secundum where the needle penetrates, of at least 3 millimeters (mm) in instances where the limbus is relatively thin. Clamp distance 1028 is preferably greater than the puncture distance to allow for adequate secundum tissue to be engaged. In one exemplary embodiment, device 404 is configured to achieve a puncture distance is in the range of 3-7 mm and preferably 3-5 mm. In another exemplary embodiment, device 404 is configured to achieve a puncture distance of approximately 4 mm. Clamp distance 1028 is preferably less than 15 mm. It should be noted that these distances are merely exemplary embodiments, and, in instances where no length is recited in the claims, in no way should the embodiments described herein be construed as limited to any particular length.
Also, upper portion 1033 can be made to extend relatively further distally than lower portion 1032 such that distal tip 430 is located distal to the distal tip 1031 of lower portion 1032. This can facilitate the motion of needle member 405 past lower portion 1032 and allow easier penetration and left atrial access.
It should be noted that upper portion 1033 and lower portion 1032 can be pivoted with respect to each other, or opened, by any amount in accordance with the needs of the application including amounts greater than or equal to 90 degrees. A mechanical stop is preferably included to prevent travel of the upper portion 1033 past the desired position. A stop is also preferably included between distal tip 430 and upper portion 1033 that prevents rotation of distal tip 430 too far forward in a distal direction and thereby maintains the desired orientation with the body tissue.
In both
Preferably, lower portion 1032 is configured to minimize surface friction to tissue as lower portion 1032 is advanced into PFO tunnel 215. For instance, one or more of teeth 1012 are preferably angled to have a relatively higher degree of surface friction against tissue when teeth 1012 are translated proximally than when translated distally. This allows lower portion 1032 to be easily advanced into PFO tunnel 215 while at the same time adequately engaging secundum 210 once properly positioned within tunnel 215.
Both reinforcement members 1044 and coil reinforcement 1045 can extend along any length of OA delivery member 401 including the entire length, or any portion of the length in which additional reinforcement is desired. Reinforcement members 1044 and coil reinforcement 1045 can be used together or each individually as desired. In addition, any number of one or more reinforcement members 1044 can be used and any number of one or more coil reinforcements 1045 can be used. Reinforcement members 1044 and coil reinforcement 1045 can be made of any desired reinforcing material such as nitinol, stainless steel, cobalt-chrome alloys and the like. Reinforcement can decrease the tendency of sheath 1016 to stretch, can prevent buckling, kinking or other radial distortion when OA delivery member 401 is bent or deflected (such as during off axis delivery), and can provide a high radiopacity.
Also, use of reinforcement members 1044 can increase the tendency of sheath 1016 to deflect in a given direction. For instance, if reinforcement members 1044 are disposed at opposite sides of sheath 1016 as depicted here, sheath 1016 will be more likely to deflect up or down in directions 1046 and 1047 as shown. This can provide benefit during the delivery procedure by increasing the likelihood of OA delivery member 401 to deflect in a desired direction. Furthermore, sheath 1016, if fabricated from certain polymeric materials recognized by those of skill in the art, can exhibit a natural tendency to deflect in a given direction and this natural tendency can be used with reinforcement members 1044 to provide deflection in a desired direction. In addition, some manufacturing processes (e.g., extrusion and the like) can be used to orient the polymeric chains of sheath 1016 advantageously to provide the desired directionality. Furthermore, a relatively thinner portion of sheath 1016, which extends along the length of sheath 1016 in the desired region, can improve the tendency of sheath 1016 to deflect in a particular direction.
It should be noted that any feature, function, method or component of any embodiment described with respect to
Distal advancement of tracking element 620 is preferably limited (e.g., by a distal stop in body member 101 or the proximal controller), at which point continued advancement of centering arms 602 will cause arms 602 to reach their fully outwardly extended position. Centering arms 602 are preferably actively deployed, i.e., forcibly extended outwards through distal advancement of the arms by the user. However, arms 602 can also be passively deployed, i.e., exposure of arms 602 from recesses 605 allows arms 602 to spring outwards autonomously.
Preferably, after centering arms 602 are fully deployed, body member 101 can be distally advanced until upper jaw 1033 contacts limbus 211 as depicted in
Also, centering arms 602 can be deployed while within the PFO tunnel, as opposed to deployment prior to advancement into the PFO tunnel as shown. The use of centering arms 602 helps ensure that upper jaw 1033 contacts limbus 211 in a position aligned along the center of the PFO tunnel. This helps upper jaw 1033 grasp the center of limbus 211 and results in deployment of the implantable device through the center of the PFO tunnel.
Region 47O of
This embodiment allows for deployment of the closure element within the space 623 between centering arm 602-1 and centering arm 602-2. Prior to implantation of the closure device, guidewire 641 can be retracted, leaving tracking element 620 and centering arms 602-1 and 602-2 behind. Next, needle member 405 can be advanced through septal wall 207 and left atrial anchors 360-1 and 360-2 are deployed and pulled up against the left atrial surface of septal wall 207. Once the left atrial anchors 360 are in contact with the tissue, centering arm 602-1 is retracted, which disengages its distal end from a socket (not shown) in tracking element 620. Retraction of tracking element 620 forces the closure device against the proximal face 622 of tracking element 620. Face 622 is sloped or angled to allow the closure device to slide past tracking element 620 as it is refracted further. Thus, the closure device can be implanted in space 623 with the centering device 106 having the capability to open up and allow removal of system 100 past the implanted closure device. In this embodiment, the proximal controller (not shown) can be configured to distally advance centering arms 602 together in one forward motion. The use interface to the proximal controller can allow retraction of centering arms 602 with two or more motions, i.e., independently, or can allow retraction of both arms 602 in one motion using a fast rate of retraction for arm 602-1 and a slower (or altogether delayed) retraction of centering arm 602-2.
Cam locking element 1330 and locking tab 1323 together form a position dependent lock mechanism that prevents advancement of needle member 405 (not shown) until centering device 106 (not shown) is retracted from the deployed to the undeployed state, in order to prevent the deployment (and subsequent trapping) of the closure device within the deployed centering arms.
Here, centering actuator knob 1302 is in its proximal-most position and locking tab 1323 is out of alignment with cam locking element 1330, meaning cam 1104 can rotate without interference from locking tab 1323. This is also shown in
Also shown here are a tactile feedback element 1308 and an optional locking member 1307. Actuator 1301 is configured to slide between a proximal position, where centering device 106 is undeployed, and a distal position, where centering device 106 is fully deployed, i.e., centering arms 602 have been fully extended outwards from body member 101 and tracking element 620 has been fully advanced distally. Tactile feedback element 1308 is coupled with actuator 1301 and is configured to provide tactile feedback to the user when the actuator 1301 is in the proximal position and the distal position.
In this embodiment, this feature is implemented by use of a spring-ball plunger that interfaces with corresponding detents 1317 and 1318 in housing cover 1305. When actuator 1301 is in the proximal position, the spring-ball is located within detent 1317 and the user must provide the required amount of force to drive plunger 1308 from within detent 1317 and towards distal detent 1318, at which point the spring-ball plunger will click into detent 1318 and will click and will provide the user with noticeable tactile feedback that the device has been fully advanced.
Sleeves 1310 and 1312 receive centering arms 602 and arm hub 1319 is used to control the advancement of centering arms 602 (or retraction thereof). Sleeve 1311 receives core wire 621 and core hub 1306 is used to control the advancement or retraction of core wire 621. Sleeves 1310-1312 can be adhesively bonded to the respective hubs 1306 and 1319. Alternatively, sleeves 1310-1312 can be omitted and the core member 621 and centering arms 602 can be directly connected to the respective hubs 1306 and 1319.
Locking member 1307 is configured here as a leaf spring having a proximal wire loop abutment 1316 and a distal ring 1314 that is configured to mate with projection (or peg) 1315 in actuator 1301. Leaf spring 1307 is configured to deflect outwards away from actuator 1301. Leaf spring 1307 is aligned with pocket 1321 such that wire loop 1316 can extend into pocket 1321 and can contact the proximal end of core hub 1306. When wire loop 1316 is pressed behind the proximal end of core hub 1306, hubs 1306 and 1319 are effectively locked in position with respect to each other.
This arrangement is shown in
A channel or recess 1309 is present at a position distal to raised surface 1322 in housing base 1304. When wire loop 1316 reaches channel 1309, leaf spring 1307 becomes free to deflect outwards away from actuator 1301. The result is that further distal translation of actuator 1301 causes centering arms 602 to continue to deploy outwards away from body member 101. But, because leaf spring 1307 is no longer in contact with core hub 1306, hub 1306 is free floating with respect to actuator 1301 and remains in a static position. Actuator 1301 can then be advanced until plunger element 1308 mates with distal detent 1318 at which point centering arms 602 have been fully deployed.
Different amounts of travel are required to deploy centering arms 602 as opposed to core wire 621 and therefore it becomes desirable to allow core hub 1306 to become detached from the continued advancement of arm hub 1319 (and actuator 1301). Preferably, core hub 1306 experiences a significant amount of device surface friction that causes hub 1306 to remain in a static position after leaf spring 1307 is released. Alternatively, a mechanical stop can be used either in controller 900 or at the distal end of the catheter. This friction can be generated by the routing of core wire 621 through the various channels in proximal controller 900 and the vasculature of the patient itself, which can be fairly tortuous.
The entire procedure can then be performed in reverse to retract centering arms 602 into the undeployed position. The user retracts actuator 1301 such that plunger element 1308 becomes detached from detent 1318 at which point arm hub 1319 moves proximally with respect to core hub 1306 as the two are unattached due to the presence of channel 1309. Hub 1306 remains in a static position due to the friction applied by the catheter and the proximal controller 900. Once core hub 1306 has reached the distal end of seat 1321, it begins to move proximally with the rest of actuator 1301. Leaf spring 1307 contacts raised surface 1322 and moves back into the position that locks core hub 1306 with respect to arm hub 1319 and the entire assembly can be continually retracted until plunger element 1308 interfaces with proximal detent 1317, at which point retraction of centering device 106 is complete.
Actuator subassembly 1360 includes a main body 1361 that is pivotably coupled with a selector body 1362 via hinge 1368. Actuator subassembly 1360 also includes a hub guide 1364 configured to slidably receive core hub 1306 and centering arm hub 1319. Each of hubs 1306 and 1319 can slide proximally and distally along guide 1364, which in this embodiment is configured as a rod. Main body portion 1361 also includes a strut 1363 upon which a knob or other type of handle can be mounted. A tactile feedback element 1308, configured in this example as a spring ball plunger, is located on the top side (as shown here) of subassembly 1360 and is configured to interface with corresponding detents 1317 and 1318 located on housing base 1304.
As in the previous embodiment, core hub 1306 is coupled with a sleeve 1311 which is configured to receive the core wire (not shown) and aid in resistance to buckling during advancement of the core wire. Centering arm hub 1319 is likewise coupled with sleeves 1310 and 1312 for receiving the centering arms (not shown). Sleeves 1310-1312 can be adhesively bonded within the oval-shaped pockets shown on the backside of core hub 1306 and centering arm hub 1319 in
Strut 1363, of main body portion 1361, is configured to extend through slot 1342 in housing cover 1305. Housing cover 1305 also includes a deflectable locking element 1343 which is configured to lock core hub 1306 in place and will be described in more detail below.
Centering arm hub 1319 includes a hub projection 1366 which is slidably received within a curved slot (or track) 1367 in selector body 1362. The interface mechanism formed by projection 1366 and slot 1367 allows hub 1319 to remain coupled to selector body 1362 while selector body 1362 remains free to pivot with respect to hub 1319. Selector body 1362 includes a guide projection 1365, which is configured to be received within a slot (or track) in guide platform 1350.
The letters (A, B, C, D, E, F) appearing on
Position A corresponds to the initial position of deployment of the centering device in a medical procedure (PFO closure or other). In this starting position, selector body 1362 is in a fully raised position as shown in
As actuator subassembly 1360 is advanced to position B, the core member and centering arm members (not shown) move together distally by an equivalent amount. At position B, the path of slot 1351 changes to guide subassembly 1360 both distally and laterally, causing selector body 1362 to rotate from the position shown in
Once actuator subassembly 1360 has been advanced to position C shown in FIG. MD, selector body 1362 has pivoted downwards by an amount sufficient to release core hub 1306 and allow distal forward movement of arm hub 1319 alone. This is shown in the top-down view of
Core hub 1306 is restricted from proximal retraction by deflectable locking element 1343 on housing cover 1305 (see
Upon reaching position D in guide platform 1350, locking element 1352 engages guide projection 1365 and prevents proximal travel of subassembly 1370 back towards position C. Locking element 1352 is deflectable but biased towards the position shown here, and ensures unidirectional motion through positions C and D. Position D marks the end of forward travel for the centering arms contained within sleeves 1310 and 1312. At this position, the centering arms are preferably fully deployed outwardly from the catheter (e.g., body member 101—not shown).
When ready to retract the centering arms back into the housed location, the user will retract actuator subassembly 1360 proximally from position D to position E, which retracts arm hub 1319 with respect to core hub 1306, which is held in place by locking element 1343. Rear surface 1373 on projection 1371 of selector body 1362. engages a corresponding opposing surface 1344 on the inner side of housing cover 1305 (see
Referring back to
In
To retract the centering arms, knob 1302 is retracted proximally back towards core hub 1306. The user brings arm hub 1319 into contact with core hub 1306 and drives core hub 1306 backwards to remove tabs 1386 from recesses 1381. Although shown here to be stepped, the proximal edge of recess 1383 can be sloped or rounded to allow easier retraction of core hub 1306. It should also be noted that a slot 1324 is present in housing base 1304 through which a locking tab 1323 can extend (see description with respect to
It should be noted that while the term “centering” is used herein to describe centering of a device with respect to a PFO tunnel, one can place the device in any desired position with respect to the PFO tunnel, offset to either the left or right, depending on the design and outward travel of the centering components. The term “lateral positioning” can be used instead of “centering.” The centering components can be used to spread or space the PFO tunnel sidewalls apart, and can also be referred to as “spreading” components.
The devices and methods herein may be used in any part of the body, in order to treat a variety of disease states. Of particular interest are applications within hollow organs including but not limited to the heart and blood vessels (arterial and venous), lungs and air passageways, digestive organs (esophagus, stomach, intestines, biliary tree, etc.). The devices and methods will also find use within the genitourinary tract in such areas as the bladder, urethra, ureters, and other areas.
Furthermore, the off-axis delivery systems may be used to pierce tissue and deliver medication, fillers, toxins, and the like in order to offer benefit to a patient. For instance, the device could be used to deliver bulking agent such as collagen, pyrolytic carbon beads, and/or various polymers to the urethra to treat urinary incontinence and other urologic conditions or to the lower esophagus/upper stomach to treat gastroesophageal reflux disease. Alternatively, the devices could be used to deliver drug or other agent to a preferred location or preferred depth within an organ. For example, various medications could be administered into the superficial or deeper areas of the esophagus to treat Barrett's esophagus, or into the heart to promote angiogenesis or myogenesis. Alternatively, the off-axis system can be useful in taking biopsies, both within the lumen and deep into the lumen. For example, the system could be used to take bronchoscopic biopsy specimens of lymph nodes that are located outside of the bronchial tree or flexible endoscopic biopsy specimens that are located outside the gastrointestinal tract. The above list is not meant to limit the scope of the inventive subject matter.
In some embodiments, the off-axis delivery system is used with an anchoring means in order to anchor the device to a location within the body prior to rotation of the off-axis system. This anchoring means may involve the use of a tissue grasper or forceps. It should be noted that any device or set of devices can be advanced within the lumen of the off-axis delivery system, including but not limited to needles, biopsy forceps, aspiration catheters, drug infusion devices, brushes, stents, balloon catheters, drainage catheters, and the like.
While the subject matter described herein is susceptible to various modifications and alternative forms, a specific example thereof has been shown in the drawings and is herein described in detail. It should be understood, however, that the subject matter described herein is not to be limited to the particular form disclosed, but to the contrary, is to cover all modifications, equivalents, and alternatives falling within the spirit of the disclosure.
This application is a continuation-in-part of U.S. patent application Ser. No. 12/176,175, filed Jul. 18, 2008 now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 11/744,784, filed May 4, 2007 now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 11/427,572, filed Jun. 29, 2006 now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 11/175,814, filed Jul. 5, 2005 now abandoned, each of which are fully incorporated herein by reference. This application is also a continuation-in-part of U.S. patent application Ser. No. 11/295,338, filed Dec. 5, 2005 now abandoned, which is fully incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2670673 | Gordon et al. | Mar 1954 | A |
3874388 | King et al. | Apr 1975 | A |
3875648 | Bone | Apr 1975 | A |
4006747 | Kronenthal et al. | Feb 1977 | A |
4007743 | Blake | Feb 1977 | A |
4316469 | Kapitanov | Feb 1982 | A |
4576162 | McCorkle | Mar 1986 | A |
4601718 | Possis et al. | Jul 1986 | A |
4665906 | Jervis | May 1987 | A |
4669473 | Richards et al. | Jun 1987 | A |
4696300 | Anderson | Sep 1987 | A |
4702250 | Ovil et al. | Oct 1987 | A |
4705040 | Mueller et al. | Nov 1987 | A |
4721115 | Owens | Jan 1988 | A |
4741336 | Failla et al. | May 1988 | A |
4779616 | Johnson | Oct 1988 | A |
4800890 | Cramer | Jan 1989 | A |
4802478 | Powell | Feb 1989 | A |
4836204 | Landymore et al. | Jun 1989 | A |
4850960 | Grayzel | Jul 1989 | A |
4861336 | Helzel | Aug 1989 | A |
4878893 | Chin | Nov 1989 | A |
4892098 | Sauer | Jan 1990 | A |
4902508 | Badylak et al. | Feb 1990 | A |
4917089 | Sideris | Apr 1990 | A |
4929246 | Sinofsky | May 1990 | A |
4946467 | Ohi et al. | Aug 1990 | A |
4985014 | Orejola | Jan 1991 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5037433 | Wilk et al. | Aug 1991 | A |
5041129 | Hayhurst et al. | Aug 1991 | A |
5049153 | Nakao et al. | Sep 1991 | A |
5067957 | Jervis | Nov 1991 | A |
5073166 | Parks et al. | Dec 1991 | A |
5108420 | Marks | Apr 1992 | A |
5112310 | Grobe | May 1992 | A |
5171218 | Fonger et al. | Dec 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5190050 | Nitzsche | Mar 1993 | A |
5190528 | Fonger et al. | Mar 1993 | A |
5190546 | Jervis | Mar 1993 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5219358 | Bendel et al. | Jun 1993 | A |
5222974 | Kensey et al. | Jun 1993 | A |
5236440 | Hlavacek | Aug 1993 | A |
5242427 | Bilweis | Sep 1993 | A |
5250054 | Li | Oct 1993 | A |
5250055 | Moore et al. | Oct 1993 | A |
5257637 | El Gazayerli | Nov 1993 | A |
5281234 | Wilk et al. | Jan 1994 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5284488 | Sideris | Feb 1994 | A |
5290272 | Burstein et al. | Mar 1994 | A |
5290278 | Anderson | Mar 1994 | A |
5300065 | Anderson | Apr 1994 | A |
5304184 | Hathaway et al. | Apr 1994 | A |
5304185 | Taylor | Apr 1994 | A |
5312341 | Turi | May 1994 | A |
5312435 | Nash et al. | May 1994 | A |
5318525 | West et al. | Jun 1994 | A |
5330488 | Goldrath | Jul 1994 | A |
5330496 | Alferness | Jul 1994 | A |
5334191 | Poppas et al. | Aug 1994 | A |
5334217 | Das | Aug 1994 | A |
5357979 | Imran | Oct 1994 | A |
5364410 | Failla et al. | Nov 1994 | A |
5370679 | Atlee, III | Dec 1994 | A |
5383852 | Stevens-Wright | Jan 1995 | A |
5387227 | Grice | Feb 1995 | A |
5394880 | Atlee, III | Mar 1995 | A |
5403329 | Hinchcliffe | Apr 1995 | A |
5403338 | Milo | Apr 1995 | A |
5409469 | Schaerf | Apr 1995 | A |
5409481 | Poppas et al. | Apr 1995 | A |
5413584 | Schulze | May 1995 | A |
5417699 | Klein et al. | May 1995 | A |
5417713 | Cohen | May 1995 | A |
5421338 | Crowley et al. | Jun 1995 | A |
5425744 | Fagan et al. | Jun 1995 | A |
5431696 | Atlee, III | Jul 1995 | A |
5433727 | Sideris | Jul 1995 | A |
5441504 | Pohndorf et al. | Aug 1995 | A |
5443478 | Purdy | Aug 1995 | A |
5451235 | Lock et al. | Sep 1995 | A |
5461235 | Cottrell et al. | Oct 1995 | A |
5462560 | Stevens | Oct 1995 | A |
5462561 | Vode | Oct 1995 | A |
5474573 | Hatcher | Dec 1995 | A |
5478353 | Yoon | Dec 1995 | A |
5486183 | Middleman et al. | Jan 1996 | A |
5486193 | Bourne et al. | Jan 1996 | A |
5503634 | Christy | Apr 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5507811 | Koike et al. | Apr 1996 | A |
5522873 | Jackman et al. | Jun 1996 | A |
5527388 | Berke et al. | Jun 1996 | A |
5545138 | Fugoso et al. | Aug 1996 | A |
5548872 | Oetiker | Aug 1996 | A |
5554162 | DeLange | Sep 1996 | A |
5570671 | Hickey | Nov 1996 | A |
5573540 | Yoon | Nov 1996 | A |
5573542 | Stevens | Nov 1996 | A |
5575772 | Lennox | Nov 1996 | A |
5577299 | Thompson et al. | Nov 1996 | A |
5578045 | Das | Nov 1996 | A |
5582616 | Bolduc et al. | Dec 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5601571 | Moss | Feb 1997 | A |
5605696 | Eury et al. | Feb 1997 | A |
5618311 | Gryskiewicz | Apr 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5626599 | Bourne et al. | May 1997 | A |
5634936 | Linden et al. | Jun 1997 | A |
5645557 | Yoon | Jul 1997 | A |
5649950 | Bourne et al. | Jul 1997 | A |
5658280 | Issa | Aug 1997 | A |
5662621 | Lafontaine | Sep 1997 | A |
5662643 | Kung et al. | Sep 1997 | A |
5682906 | Sterman et al. | Nov 1997 | A |
5702368 | Stevens et al. | Dec 1997 | A |
5702421 | Schneidt | Dec 1997 | A |
5709224 | Behl et al. | Jan 1998 | A |
5709707 | Lock et al. | Jan 1998 | A |
5713867 | Morris | Feb 1998 | A |
5713911 | Racenet et al. | Feb 1998 | A |
5714297 | Chamberlain et al. | Feb 1998 | A |
5716367 | Koike et al. | Feb 1998 | A |
5720754 | Middleman et al. | Feb 1998 | A |
5722981 | Stevens | Mar 1998 | A |
5725512 | Swartz et al. | Mar 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5725554 | Simon et al. | Mar 1998 | A |
5728151 | Garrison et al. | Mar 1998 | A |
5733294 | Forber et al. | Mar 1998 | A |
5738652 | Boyd et al. | Apr 1998 | A |
5741429 | Donadio, III et al. | Apr 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5759170 | Peters | Jun 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5772672 | Toy et al. | Jun 1998 | A |
5776162 | Kleshinski | Jul 1998 | A |
5782860 | Epstein et al. | Jul 1998 | A |
5792094 | Stevens et al. | Aug 1998 | A |
5797960 | Stevens et al. | Aug 1998 | A |
5807339 | Bostrom et al. | Sep 1998 | A |
5810882 | Bolduc et al. | Sep 1998 | A |
5810884 | Kim | Sep 1998 | A |
5814016 | Valley et al. | Sep 1998 | A |
5814068 | Koike et al. | Sep 1998 | A |
5814097 | Sterman et al. | Sep 1998 | A |
5823956 | Roth et al. | Oct 1998 | A |
5827216 | Igo et al. | Oct 1998 | A |
5829447 | Stevens et al. | Nov 1998 | A |
5836311 | Borst et al. | Nov 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855614 | Stevens et al. | Jan 1999 | A |
5861003 | Latson et al. | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5868702 | Stevens et al. | Feb 1999 | A |
5868733 | Ockuly et al. | Feb 1999 | A |
5868753 | Schatz | Feb 1999 | A |
5879366 | Shaw et al. | Mar 1999 | A |
5879499 | Corvi | Mar 1999 | A |
5885238 | Stevens et al. | Mar 1999 | A |
5893856 | Jacob et al. | Apr 1999 | A |
5895404 | Ruiz | Apr 1999 | A |
5902319 | Daley | May 1999 | A |
5904703 | Gilson | May 1999 | A |
5908428 | Scirica et al. | Jun 1999 | A |
5910150 | Saadat | Jun 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5913810 | Andre | Jun 1999 | A |
5913842 | Boyd et al. | Jun 1999 | A |
5919200 | Stambaugh et al. | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5927284 | Borst et al. | Jul 1999 | A |
5928181 | Coleman et al. | Jul 1999 | A |
5928250 | Koike et al. | Jul 1999 | A |
5931848 | Saadat | Aug 1999 | A |
5941899 | Granger et al. | Aug 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5947997 | Pavcnik et al. | Sep 1999 | A |
5955110 | Patel et al. | Sep 1999 | A |
5967977 | Mullis et al. | Oct 1999 | A |
5972013 | Schmidt | Oct 1999 | A |
5976174 | Ruiz | Nov 1999 | A |
5980503 | Chin | Nov 1999 | A |
5989268 | Pugsley, Jr. et al. | Nov 1999 | A |
5993475 | Lin et al. | Nov 1999 | A |
6007563 | Nash et al. | Dec 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6013052 | Durman et al. | Jan 2000 | A |
6015378 | Borst et al. | Jan 2000 | A |
6015417 | Reynolds, Jr. | Jan 2000 | A |
6024756 | Huebsch et al. | Feb 2000 | A |
6027476 | Sterman et al. | Feb 2000 | A |
6030007 | Bassily et al. | Feb 2000 | A |
6036699 | Andreas et al. | Mar 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6056760 | Koike et al. | May 2000 | A |
6071271 | Baker et al. | Jun 2000 | A |
6071292 | Makower et al. | Jun 2000 | A |
6077281 | Das | Jun 2000 | A |
6077291 | Das | Jun 2000 | A |
6079414 | Roth | Jun 2000 | A |
6080182 | Shaw et al. | Jun 2000 | A |
6090084 | Hassett et al. | Jul 2000 | A |
6090096 | St. Goar et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6095997 | French et al. | Aug 2000 | A |
6110145 | Macoviak | Aug 2000 | A |
6113609 | Adams | Sep 2000 | A |
6113610 | Poncet | Sep 2000 | A |
6113611 | Allen et al. | Sep 2000 | A |
6117145 | Wood et al. | Sep 2000 | A |
6117159 | Huebsch et al. | Sep 2000 | A |
6126658 | Baker | Oct 2000 | A |
6127410 | Duhaylongsod | Oct 2000 | A |
6132438 | Fleischman et al. | Oct 2000 | A |
6135981 | Dyke | Oct 2000 | A |
6142975 | Jalisi et al. | Nov 2000 | A |
6149664 | Kurz | Nov 2000 | A |
6152141 | Stevens et al. | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6162195 | Igo et al. | Dec 2000 | A |
6162202 | Sicurelli et al. | Dec 2000 | A |
6165183 | Kuehn et al. | Dec 2000 | A |
6165204 | Levinson et al. | Dec 2000 | A |
6171329 | Shaw et al. | Jan 2001 | B1 |
6171338 | Talja et al. | Jan 2001 | B1 |
6174322 | Schneidt | Jan 2001 | B1 |
6179809 | Khairkhahan et al. | Jan 2001 | B1 |
6187039 | Hiles et al. | Feb 2001 | B1 |
6200313 | Abe et al. | Mar 2001 | B1 |
6206895 | Levinson | Mar 2001 | B1 |
6206907 | Marino et al. | Mar 2001 | B1 |
6214029 | Thill et al. | Apr 2001 | B1 |
6221092 | Koike et al. | Apr 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6245080 | Levinson | Jun 2001 | B1 |
6254550 | McNamara et al. | Jul 2001 | B1 |
6270490 | Hahnen | Aug 2001 | B1 |
6270515 | Linden et al. | Aug 2001 | B1 |
6275730 | KenKnight et al. | Aug 2001 | B1 |
6277138 | Levinson et al. | Aug 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6280432 | Turovskiy et al. | Aug 2001 | B1 |
6280460 | Bolduc et al. | Aug 2001 | B1 |
6287317 | Makower et al. | Sep 2001 | B1 |
6290674 | Roue et al. | Sep 2001 | B1 |
6293920 | Sweezer et al. | Sep 2001 | B1 |
6302903 | Mulier et al. | Oct 2001 | B1 |
6305378 | Lesh | Oct 2001 | B1 |
6306150 | Levinson | Oct 2001 | B1 |
6306424 | Vyakarnam et al. | Oct 2001 | B1 |
6308090 | Tu et al. | Oct 2001 | B1 |
6309415 | Pulnev et al. | Oct 2001 | B1 |
6312446 | Huebsch et al. | Nov 2001 | B1 |
6319263 | Levinson | Nov 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6336898 | Borst et al. | Jan 2002 | B1 |
6342064 | Koike et al. | Jan 2002 | B1 |
6346074 | Roth | Feb 2002 | B1 |
6346099 | Altman | Feb 2002 | B1 |
6346112 | Adams | Feb 2002 | B2 |
6350229 | Borst et al. | Feb 2002 | B1 |
6352531 | O'Conner et al. | Mar 2002 | B1 |
6352552 | Levinson et al. | Mar 2002 | B1 |
6355052 | Neuss et al. | Mar 2002 | B1 |
6364826 | Borst et al. | Apr 2002 | B1 |
6371906 | Borst et al. | Apr 2002 | B1 |
6375671 | Kobayashi et al. | Apr 2002 | B1 |
6379368 | Corcoran et al. | Apr 2002 | B1 |
6387104 | Pugsley, Jr. et al. | May 2002 | B1 |
6394948 | Borst et al. | May 2002 | B1 |
6398796 | Levinson | Jun 2002 | B2 |
6401720 | Stevens et al. | Jun 2002 | B1 |
6402772 | Amplatz et al. | Jun 2002 | B1 |
6416493 | Del Giglio | Jul 2002 | B1 |
6419669 | Frazier et al. | Jul 2002 | B1 |
6432059 | Hickey | Aug 2002 | B2 |
6436088 | Frazier et al. | Aug 2002 | B2 |
6440152 | Gainor et al. | Aug 2002 | B1 |
6458100 | Roue et al. | Oct 2002 | B2 |
6464640 | Guracar et al. | Oct 2002 | B1 |
6464645 | Park et al. | Oct 2002 | B1 |
6482224 | Michler et al. | Nov 2002 | B1 |
6482228 | Norred | Nov 2002 | B1 |
6485504 | Johnson et al. | Nov 2002 | B1 |
6488706 | Solymar | Dec 2002 | B1 |
6497698 | Fonger et al. | Dec 2002 | B1 |
6506205 | Goldberg et al. | Jan 2003 | B2 |
6532388 | Hill et al. | Mar 2003 | B1 |
6537300 | Girton | Mar 2003 | B2 |
6551272 | Gobel | Apr 2003 | B2 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6551344 | Thill | Apr 2003 | B2 |
6560489 | Hauck | May 2003 | B2 |
6562051 | Bolduc et al. | May 2003 | B1 |
6562052 | Nobles et al. | May 2003 | B2 |
6572593 | Daum | Jun 2003 | B1 |
6579259 | Stevens et al. | Jun 2003 | B2 |
6585716 | Altman | Jul 2003 | B2 |
6592552 | Schmidt | Jul 2003 | B1 |
6592557 | Barbut | Jul 2003 | B2 |
6596013 | Yang et al. | Jul 2003 | B2 |
6606513 | Lardo et al. | Aug 2003 | B2 |
6613062 | Leckrone et al. | Sep 2003 | B1 |
6623508 | Shaw et al. | Sep 2003 | B2 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6626841 | Atlee, III | Sep 2003 | B1 |
6626890 | Nguyen et al. | Sep 2003 | B2 |
6626899 | Houser et al. | Sep 2003 | B2 |
6626930 | Allen et al. | Sep 2003 | B1 |
6629534 | Zheng et al. | Oct 2003 | B1 |
6632223 | Keane | Oct 2003 | B1 |
6645225 | Atkinson | Nov 2003 | B1 |
6650923 | Lesh et al. | Nov 2003 | B1 |
6651672 | Roth | Nov 2003 | B2 |
6656206 | Corcoran et al. | Dec 2003 | B2 |
6659981 | Stewart et al. | Dec 2003 | B2 |
6662045 | St. Goar et al. | Dec 2003 | B2 |
6663639 | Laufer et al. | Dec 2003 | B1 |
6666861 | Grabek | Dec 2003 | B1 |
6679268 | Stevens et al. | Jan 2004 | B2 |
6685728 | Sinnott et al. | Feb 2004 | B2 |
6689062 | Mesallum | Feb 2004 | B1 |
6692471 | Boudreaux | Feb 2004 | B2 |
6692512 | Jang | Feb 2004 | B2 |
6695838 | Wellman et al. | Feb 2004 | B2 |
6699231 | Sterman et al. | Mar 2004 | B1 |
6702835 | Ginn | Mar 2004 | B2 |
6706033 | Martinez et al. | Mar 2004 | B1 |
6706047 | Trout et al. | Mar 2004 | B2 |
6712804 | Roue et al. | Mar 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6726662 | Altman | Apr 2004 | B2 |
6730061 | Cuschieri et al. | May 2004 | B1 |
6735471 | Hill et al. | May 2004 | B2 |
6736828 | Adams et al. | May 2004 | B1 |
6746404 | Schwartz | Jun 2004 | B2 |
6746456 | Xiao | Jun 2004 | B2 |
6749617 | Palasis et al. | Jun 2004 | B1 |
6773441 | Laufer et al. | Aug 2004 | B1 |
6776784 | Ginn | Aug 2004 | B2 |
6776797 | Blom et al. | Aug 2004 | B1 |
6783499 | Schwartz | Aug 2004 | B2 |
6790218 | Jayaraman | Sep 2004 | B2 |
6802840 | Chin et al. | Oct 2004 | B2 |
6821265 | Bertolero et al. | Nov 2004 | B1 |
6840246 | Downing | Jan 2005 | B2 |
6854467 | Boekstegers | Feb 2005 | B2 |
6855116 | Atlee, III | Feb 2005 | B2 |
6866650 | Stevens et al. | Mar 2005 | B2 |
6878118 | Atlee, III | Apr 2005 | B2 |
6882883 | Condie et al. | Apr 2005 | B2 |
6889694 | Hooven | May 2005 | B2 |
6899704 | Sterman et al. | May 2005 | B2 |
6902545 | Bertolero et al. | Jun 2005 | B2 |
6913600 | Valley et al. | Jul 2005 | B2 |
6913607 | Ainsworth et al. | Jul 2005 | B2 |
6915149 | Ben-Haim | Jul 2005 | B2 |
6918890 | Schmidt | Jul 2005 | B2 |
6918908 | Bonner et al. | Jul 2005 | B2 |
6929011 | Knudson et al. | Aug 2005 | B2 |
6932792 | St. Goar et al. | Aug 2005 | B1 |
6932811 | Hooven et al. | Aug 2005 | B2 |
6934583 | Weinberg et al. | Aug 2005 | B2 |
6939348 | Malecki et al. | Sep 2005 | B2 |
6939361 | Kleshinski | Sep 2005 | B1 |
6952613 | Swoyer et al. | Oct 2005 | B2 |
6953466 | Palasis et al. | Oct 2005 | B2 |
6955175 | Steven et al. | Oct 2005 | B2 |
6960220 | Marino et al. | Nov 2005 | B2 |
6971998 | Rosenman et al. | Dec 2005 | B2 |
6976990 | Mowry | Dec 2005 | B2 |
6991635 | Takamoto et al. | Jan 2006 | B2 |
6994094 | Schwartz | Feb 2006 | B2 |
6994713 | Berg et al. | Feb 2006 | B2 |
7001415 | Hooven | Feb 2006 | B2 |
7004952 | Nobles et al. | Feb 2006 | B2 |
7018390 | Turovskiy et al. | Mar 2006 | B2 |
7020518 | Zheng et al. | Mar 2006 | B2 |
7039467 | Hauck | May 2006 | B2 |
7044135 | Lesh | May 2006 | B2 |
7048733 | Hartley et al. | May 2006 | B2 |
7056331 | Kaplan et al. | Jun 2006 | B2 |
7083628 | Bachman | Aug 2006 | B2 |
7087072 | Marino et al. | Aug 2006 | B2 |
7090683 | Brock et al. | Aug 2006 | B2 |
7090686 | Nobles et al. | Aug 2006 | B2 |
7094244 | Schreck | Aug 2006 | B2 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7101395 | Tremulis et al. | Sep 2006 | B2 |
7108660 | Stephens et al. | Sep 2006 | B2 |
7112219 | Vidlund et al. | Sep 2006 | B2 |
7113831 | Hooven | Sep 2006 | B2 |
7115135 | Corcoran et al. | Oct 2006 | B2 |
7186251 | Malecki et al. | Mar 2007 | B2 |
7288105 | Oman et al. | Oct 2007 | B2 |
7320692 | Bender et al. | Jan 2008 | B1 |
7507252 | Lashinski et al. | Mar 2009 | B2 |
20010014800 | Frazier et al. | Aug 2001 | A1 |
20010034537 | Shaw et al. | Oct 2001 | A1 |
20010037129 | Thill | Nov 2001 | A1 |
20010039435 | Roue et al. | Nov 2001 | A1 |
20010041914 | Frazier et al. | Nov 2001 | A1 |
20010041915 | Roue et al. | Nov 2001 | A1 |
20010044639 | Levinson | Nov 2001 | A1 |
20010049492 | Frazier et al. | Dec 2001 | A1 |
20020010481 | Jayaraman | Jan 2002 | A1 |
20020019648 | Akerfeldt et al. | Feb 2002 | A1 |
20020026208 | Roe et al. | Feb 2002 | A1 |
20020032462 | Houser et al. | Mar 2002 | A1 |
20020035361 | Houser et al. | Mar 2002 | A1 |
20020035374 | Borillo et al. | Mar 2002 | A1 |
20020039048 | Matsuge | Apr 2002 | A1 |
20020043307 | Ishida et al. | Apr 2002 | A1 |
20020052572 | Franco et al. | May 2002 | A1 |
20020077555 | Schwartz | Jun 2002 | A1 |
20020096183 | Stevens et al. | Jul 2002 | A1 |
20020099389 | Michler et al. | Jul 2002 | A1 |
20020099437 | Anson et al. | Jul 2002 | A1 |
20020107531 | Schreck et al. | Aug 2002 | A1 |
20020111637 | Kaplan et al. | Aug 2002 | A1 |
20020111647 | Khairkhahan et al. | Aug 2002 | A1 |
20020120323 | Thompson et al. | Aug 2002 | A1 |
20020128680 | Pavlovic | Sep 2002 | A1 |
20020129819 | Feldman et al. | Sep 2002 | A1 |
20020138095 | Mazzocchi et al. | Sep 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20020183786 | Girton | Dec 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20020183823 | Pappu | Dec 2002 | A1 |
20020198563 | Gainor et al. | Dec 2002 | A1 |
20030025421 | Ebihara et al. | Feb 2003 | A1 |
20030028213 | Thill et al. | Feb 2003 | A1 |
20030033006 | Phillips et al. | Feb 2003 | A1 |
20030045893 | Ginn | Mar 2003 | A1 |
20030050665 | Ginn | Mar 2003 | A1 |
20030055455 | Yang et al. | Mar 2003 | A1 |
20030059640 | Marton et al. | Mar 2003 | A1 |
20030100920 | Akin et al. | May 2003 | A1 |
20030139819 | Beer et al. | Jul 2003 | A1 |
20030144694 | Chanduszko et al. | Jul 2003 | A1 |
20030167071 | Martin et al. | Sep 2003 | A1 |
20030191495 | Ryan et al. | Oct 2003 | A1 |
20030195530 | Thill | Oct 2003 | A1 |
20030195555 | Khairkhanhan et al. | Oct 2003 | A1 |
20030204203 | Khairkhahan et al. | Oct 2003 | A1 |
20030208232 | Blaeser et al. | Nov 2003 | A1 |
20030225421 | Peavey et al. | Dec 2003 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040073242 | Chanduszko | Apr 2004 | A1 |
20040092973 | Chanduszko et al. | May 2004 | A1 |
20040098042 | Devellian et al. | May 2004 | A1 |
20040098121 | Opolski | May 2004 | A1 |
20040133230 | Carpenter et al. | Jul 2004 | A1 |
20040133236 | Chanduszko | Jul 2004 | A1 |
20040138682 | Onuki et al. | Jul 2004 | A1 |
20040162568 | Saadat et al. | Aug 2004 | A1 |
20040176799 | Chanduszko et al. | Sep 2004 | A1 |
20040193185 | McBrayer | Sep 2004 | A1 |
20040210301 | Obermiller | Oct 2004 | A1 |
20040220596 | Frazier et al. | Nov 2004 | A1 |
20040225183 | Michlitsch et al. | Nov 2004 | A1 |
20040230185 | Malecki et al. | Nov 2004 | A1 |
20040243122 | Auth et al. | Dec 2004 | A1 |
20040267191 | Gifford, III et al. | Dec 2004 | A1 |
20040267306 | Blaeser et al. | Dec 2004 | A1 |
20050034735 | Deem et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050055050 | Alfaro | Mar 2005 | A1 |
20050059984 | Chanduszko et al. | Mar 2005 | A1 |
20050070923 | McIntosh | Mar 2005 | A1 |
20050075653 | Saadat et al. | Apr 2005 | A1 |
20050080406 | Malecki et al. | Apr 2005 | A1 |
20050119671 | Reydel et al. | Jun 2005 | A1 |
20050119675 | Adams et al. | Jun 2005 | A1 |
20050125032 | Whisenant et al. | Jun 2005 | A1 |
20050131460 | Gifford, III et al. | Jun 2005 | A1 |
20050149066 | Stafford | Jul 2005 | A1 |
20050149115 | Roue et al. | Jul 2005 | A1 |
20050187568 | Klenk et al. | Aug 2005 | A1 |
20050187588 | Stahmann et al. | Aug 2005 | A1 |
20050187620 | Pai et al. | Aug 2005 | A1 |
20050192626 | Widomski et al. | Sep 2005 | A1 |
20050192627 | Whisenant et al. | Sep 2005 | A1 |
20050192654 | Chanduszko et al. | Sep 2005 | A1 |
20050209636 | Widomski et al. | Sep 2005 | A1 |
20050216054 | Widomski et al. | Sep 2005 | A1 |
20050228434 | Amplatz et al. | Oct 2005 | A1 |
20050234509 | Widomski et al. | Oct 2005 | A1 |
20050250988 | Ewers et al. | Nov 2005 | A1 |
20050251154 | Chanduszko et al. | Nov 2005 | A1 |
20050251165 | Vaughan et al. | Nov 2005 | A1 |
20050251201 | Roue et al. | Nov 2005 | A1 |
20050256532 | Nayak et al. | Nov 2005 | A1 |
20050267493 | Schreck et al. | Dec 2005 | A1 |
20050267495 | Ginn et al. | Dec 2005 | A1 |
20050267523 | Devellian et al. | Dec 2005 | A1 |
20050267524 | Chanduszko | Dec 2005 | A1 |
20050267525 | Chanduszko | Dec 2005 | A1 |
20050267526 | Wahr et al. | Dec 2005 | A1 |
20050267529 | Crockett et al. | Dec 2005 | A1 |
20050271631 | Lee et al. | Dec 2005 | A1 |
20050273119 | Widomski et al. | Dec 2005 | A1 |
20050273124 | Chanduszko | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050277982 | Marino et al. | Dec 2005 | A1 |
20050288706 | Widomski et al. | Dec 2005 | A1 |
20050288786 | Chanduszko | Dec 2005 | A1 |
20060009800 | Christianson et al. | Jan 2006 | A1 |
20060015002 | Moaddeb et al. | Jan 2006 | A1 |
20060036282 | Wahr et al. | Feb 2006 | A1 |
20060036284 | Blaeser et al. | Feb 2006 | A1 |
20060052821 | Abbott et al. | Mar 2006 | A1 |
20060069408 | Kato | Mar 2006 | A1 |
20060079870 | Barry | Apr 2006 | A1 |
20060095052 | Chambers | May 2006 | A1 |
20060122633 | To et al. | Jun 2006 | A1 |
20060200197 | Brenzel et al. | Sep 2006 | A1 |
20060217764 | Abbott et al. | Sep 2006 | A1 |
20060241687 | Glaser et al. | Oct 2006 | A1 |
20060271089 | Alejandro et al. | Nov 2006 | A1 |
20070005018 | Tekbuchava | Jan 2007 | A1 |
20070010806 | Malecki et al. | Jan 2007 | A1 |
20070049970 | Belef et al. | Mar 2007 | A1 |
20070073337 | Abbott et al. | Mar 2007 | A1 |
20070123851 | Alejandro et al. | May 2007 | A1 |
20070185530 | Chin-Chen et al. | Aug 2007 | A1 |
20080015633 | Abbott et al. | Jan 2008 | A1 |
Number | Date | Country |
---|---|---|
42 22 291 | Jul 1992 | DE |
0 432 320 | Jun 1991 | EP |
0 553 259 | Mar 1995 | EP |
1 013 227 | Jun 2000 | EP |
1 222 897 | Jul 2002 | EP |
1 046 375 | Nov 2004 | EP |
04-226643 | Aug 1992 | JP |
WO 9205828 | Apr 1992 | WO |
WO 9206733 | Apr 1992 | WO |
WO 9625179 | Aug 1996 | WO |
WO 9631157 | Oct 1996 | WO |
WO 9742878 | Nov 1997 | WO |
WO 9802100 | Jan 1998 | WO |
WO 9807375 | Feb 1998 | WO |
WO 9902100 | Jan 1999 | WO |
WO 9918862 | Apr 1999 | WO |
WO 9918864 | Apr 1999 | WO |
WO 9918870 | Apr 1999 | WO |
WO 9918871 | Apr 1999 | WO |
WO 0007506 | Feb 2000 | WO |
WO 0027292 | May 2000 | WO |
WO 0035352 | Jun 2000 | WO |
WO 0044428 | Aug 2000 | WO |
WO 0121247 | Mar 2001 | WO |
WO 0149185 | Jul 2001 | WO |
WO 0178596 | Oct 2001 | WO |
WO 02024106 | Mar 2002 | WO |
WO 02062236 | Aug 2002 | WO |
WO 03059152 | Jul 2003 | WO |
WO 03063732 | Aug 2003 | WO |
WO 03077733 | Sep 2003 | WO |
WO 03094742 | Nov 2003 | WO |
WO 03103476 | Dec 2003 | WO |
WO 2004026146 | Apr 2004 | WO |
WO 2004043266 | May 2004 | WO |
WO 2004052213 | Jun 2004 | WO |
2004069054 | Aug 2004 | WO |
WO 2004069054 | Aug 2004 | WO |
WO 2004069055 | Aug 2004 | WO |
WO 2004086951 | Oct 2004 | WO |
WO 2004087235 | Oct 2004 | WO |
WO 2005006990 | Jan 2005 | WO |
WO 2005027752 | Mar 2005 | WO |
WO 2005034738 | Apr 2005 | WO |
WO 2005039419 | May 2005 | WO |
WO 2005074517 | Aug 2005 | WO |
WO 2005074814 | Aug 2005 | WO |
WO 2005082255 | Sep 2005 | WO |
WO 2005092203 | Oct 2005 | WO |
WO 2005110240 | Nov 2005 | WO |
WO 2005112779 | Dec 2005 | WO |
WO 2006036837 | Apr 2006 | WO |
WO 2007024615 | Mar 2007 | WO |
WO 2008024489 | Feb 2008 | WO |
WO 2008153872 | Dec 2008 | WO |
Entry |
---|
Baim, D., Percutaneous Approach, Including Transseptal and Apical Puncture, Grossman's Cardiac Catheterization, Angiography, and Intervention, 6th Ed., 2000. |
Daoud, E., et al. Intracardiac Echocardiography to Guide Transseptal Left Heart Catheterization for Radiofrequency Catheter Ablation, Journal of Cardiovascular Electrophysiology, vol. 10, No. 3, Mar. 1999. |
De Ponti, R., et al., Trans-septal catheterization for radiofrequency catheter ablation of cardiac arrhythmias, European Heart Journal, vol. 19, 1998. |
Epstein, L., et al., Nonfluoroscopic Transseptal Catheterization: Safety and Efficacy of Intracardiac Echocardiographic Guidance, Journal of Cardiovascular Electrophysciology, vol. 9, No. 6, Jun. 1998. |
Hara, H., et al., Patent Foramen Ovale: Current Pathology, Pathophysiology, and Clinical Status, Journal of the American College of Cardiology, vol. 46, No. 9, Nov. 2005:1768-1776. |
Hurrell, D., et al., Echocardiography in the Invasive Laboratory: Utility of Two-Dimensional Echocardiography in Performing Transseptal Catherization, Mayo Clinic Proc., 1998:73:126-131. |
Lesh, M., et al., Comparison of the Retrograde and Transseptal Methods for Ablation of Left Free Wall Accessory Pathways, Journal of American College of Cardiology, vol. 22, No. 2, Aug. 1993:542-549. |
Lundqvist, C., et al., Transseptal Left Heart Catheterization: A Review of 278 Studies, Clin. Cardiol. 9, Jan. 1986. |
Mitchel, J., et al., Intracardiac Ultrasound Imaging During Transseptal Catheterization, Chest, vol. 108, No. 1, Jul. 1995. |
Montenero, A., et al., Catheter Ablation of Left Accessory Atrioventricular Connections: The Transseptal Approach, Journal of Interventional Cardiology, vol. 8, No. 6 (Suppl), 1995. |
Peckham, G., et al., Combined Percutaneous Retrograde Aortic and Transseptal Left Heart Catheterization, Brit. Heart Journal, vol. 26, 1964. |
Reig, J., et al., Morphologic characteristics of the fossa ovalis as an anatomic basis for transseptal catheterization, Surg. Radio!. Anat. vol. 19, No. 5, 1997. |
Roelke, M., et al., The Technique and Safety of Transseptal Left Heart Catheterization: The Massachusetts General Hospital Experience With 1,279 Procedures, Catheterization and Cardiovascular Diagnosis, vol. 32, No. 4, Aug. 1994. |
Ruiz, C., et al., The Puncture Technique: A New Method for Transcatheter Closure of Patent Foramen Ovale, Catherization and Cardiovascular Interventions 53:369-372 (2001). |
St. Jude Medical, BRK™ Transseptal Needle (Instructions for Use), Nov. 2006. |
Szili-Torok, T., Transseptal left heart catherisation guided by intracardiac echocardiography, Heart, vol. 86, e. 11, 2001. |
Tucker, K., Transesophageal Echocardiographic Guidance of Transseptal Left Heart Catheterization During Radiofrequency Ablation of Left-Sided Accessory Pathways in Humans, PACE, vol. 19, Mar. 1996. |
Number | Date | Country | |
---|---|---|---|
20110093007 A1 | Apr 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12176175 | Jul 2008 | US |
Child | 12819911 | US | |
Parent | 11744784 | May 2007 | US |
Child | 12176175 | US | |
Parent | 11427572 | Jun 2006 | US |
Child | 11744784 | US | |
Parent | 11175814 | Jul 2005 | US |
Child | 11427572 | US | |
Parent | 11295338 | Dec 2005 | US |
Child | 12819911 | US |